



Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	501	(544/324).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/12/03 14:25
L2	801	(544/320).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/12/03 14:25
L3	856	(544/321).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/12/03 14:25
L4	1204	(514/275).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/12/03 14:26
L5	43	John.inv. and Charles.inv. and kath.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/12/03 14:26
L6	26	Michael.inv. and Joseph.inv. and luzzio.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/12/03 14:27

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	501	(544/324).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/12/03 14:25
L2	801	(544/320).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/12/03 14:25
L3	856	(544/321).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/12/03 14:25
L4	1204	(514/275).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/12/03 14:26
L5	43	John.inv. and Charles.inv. and kath.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/12/03 14:26
L6	26	Michael.inv. and Joseph.inv. and luzzio.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/12/03 14:27



chain nodes :

7 8 9 10 12 13 14 15 16 17 18 22 23

ring nodes :

1 2 3 4 5 6

chain bonds :

2-8 4-7 6-12 8-9 8-10 12-13 13-22 14-15 16-17 16-18 22-23

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

2-8 6-12 8-10 12-13 13-22 14-15 16-17 16-18

exact bonds :

4-7 8-9 22-23

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:O,S,NH

G2:N,[\*1],[\*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom  
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 22:CLASS 23:CLASS

Generic attributes :

10:

Saturation : Unsaturated

Type of Ring System : Polycyclic



10/734039

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY  
NEWS 4 OCT 03 MATHDI removed from STN  
NEWS 5 OCT 04 CA/CAPplus-Canadian Intellectual Property Office (CIPO) added  
to core patent offices  
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005  
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download  
of CAPplus documents for use in third-party analysis and  
visualization tools  
NEWS 8 OCT 27 Free KWIC format extended in full-text databases  
NEWS 9 OCT 27 DIOGENES content streamlined  
NEWS 10 OCT 27 EPFULL enhanced with additional content  
NEWS 11 NOV 14 CA/CAPplus - Expanded coverage of German academic research  
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental  
spectral property data  
  
NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.  
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT  
<http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:41:49 ON 03 DEC 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

10/734039

FILE 'REGISTRY' ENTERED AT 15:42:05 ON 03 DEC 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 2 DEC 2005 HIGHEST RN 869276-67-5  
DICTIONARY FILE UPDATES: 2 DEC 2005 HIGHEST RN 869276-67-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*


Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10734039.str



chain nodes :

7 8 9 10 12 13 14 15 16 17 18 22 23

10/734039

ring nodes :  
1 2 3 4 5 6  
chain bonds :  
2-8 4-7 6-12 8-9 8-10 12-13 13-22 14-15 16-17 16-18 22-23  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6  
exact/norm bonds :  
2-8 6-12 8-10 12-13 13-22 14-15 16-17 16-18  
exact bonds :  
4-7 8-9 22-23  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6  
isolated ring systems :  
containing 1 :

G1:O,S,NH


G2:N,[\*1],[\*2]

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom  
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 22:CLASS  
23:CLASS  
Generic attributes :  
10:  
Saturation : Unsaturated  
Type of Ring System : Polycyclic

L1 STRUCTURE UPLOADED

=> d l1  
L1 HAS NO ANSWERS  
L1 STR

10/734039



G1 O,S,NH

G2 N,[@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 15:42:39 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 16106 TO ITERATE

12.4% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01


3 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 314520 TO 329720  
PROJECTED ANSWERS: 189 TO 777

L2 3 SEA SSS SAM L1

=> d scan

L2 3 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[2-(2-piperidinyl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI)  
MF C20 H23 F3 N6 O






10/734039

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 3 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Glycine, N-[5-bromo-2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-4-pyrimidinyl]- (9CI)  
MF C14 H12 Br N5 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 3 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2H-Indol-2-one, 5-[[5-bromo-4-[methyl(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI)  
MF C19 H17 Br N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss ful  
FULL SEARCH INITIATED 15:43:00 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 322710 TO ITERATE

100.0% PROCESSED 322710 ITERATIONS 909 ANSWERS  
SEARCH TIME: 00.00.06

L3 909 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 161.76 161.97

FILE 'CAPLUS' ENTERED AT 15:43:12 ON 03 DEC 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

10/734039

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Dec 2005 VOL 143 ISS 24

FILE LAST UPDATED: 2 Dec 2005 (20051202/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 49 L3

=> d l4 1-49 bib hitstr

L4 ANSWER 1 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:1219890 CAPLUS

TI Preparation of pyrimidine derivatives for the treatment of abnormal cell growth

IN Kath, John Charles; Luzzio, Michael Joseph

PA Pfizer Inc, USA

SO U.S. Pat. Appl. Publ., 68 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 2005256145	A1	20051117	US 2005-127809	20050512
	WO 2005111023	A1	20051124	WO 2005-IB1201	20050502
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2004-571312P P 20040514

IT INDEXING IN PROGRESS

IT 717906-37-1P, 5-[[4-[(Pyridin-2-ylmethyl)amino]-5-trifluoromethylpyrimidin-2-yl]amino]-1,3-dihydroindol-2-one  
717906-38-2P, 5-[[5-Trifluoromethyl-4-(2-trifluoromethylbenzylamino)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one  
717906-39-3P, 5-[[4-[(3-Methylpyridin-2-ylmethyl)amino]-5-trifluoromethylpyrimidin-2-yl]amino]-1,3-dihydroindol-2-one  
717906-40-6P, 5-[[4-[3-(Methanesulfonyl)benzylamino]-5-trifluoromethylpyrimidin-2-yl]amino]-1,3-dihydroindol-2-one


10/734039

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. for treatment of abnormal cell growth)


RN 717906-37-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(2-pyridinylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717906-38-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[5-(trifluoromethyl)-4-[[[2-(trifluoromethyl)phenyl]methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717906-39-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[3-methyl-2-pyridinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717906-40-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:811031 CAPLUS

DN 143:213189

TI Ink-jet ink set containing phthalocyanine dyes and pyrazine-based azo dyes with high quality and good storage stability

IN Takahashi, Mari; Yasukawa, Hiroyuki; Suzuki, Takashi; Ikesu, Satoru

PA Konica Minolta Holdings, Inc., Japan

10/734039

SO Jpn. Kokai Tokkyo Koho, 90 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2005220252	A2	20050818	JP 2004-30392	20040206
PRAI	JP 2004-30392		20040206		
IT	862428-81-7				

RL: TEM (Technical or engineered material use); USES (Uses)

(production of ink-jet ink set containing phthalocyanine dyes and pyrazine-based azo dyes)

RN 862428-81-7 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 3-[2-[2-(2-benzothiazolylamino)-4-(benzoylamino)-5-pyrimidinyl]azo]-, octyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:638883 CAPLUS

DN 143:153408

TI Preparation of pyrrolo[2,1-f][1,2,4]triazine derivatives as HER1, HER2, and HER4 kinase inhibitors, and antiproliferative agents

IN Fink, Brian E.; Gavai, Ashvinikumar V.; Vite, Gregory D.; Chen, Ping; Mastalerz, Harold; Norris, Derek J.; Tokarski, John S.; Zhao, Yufen; Han, Wen-Ching

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 196 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005066176	A1	20050721	WO 2004-US43169	20041223
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2005182058 A1 20050818 US 2004-19901 20041222

PRAI US 2003-533335P P 20031229

OS MARPAT 143:153408

IT 859851-53-9P, 5-[(4-Amino-1-piperidinyl)methyl]-N-(4-methyl-2-pyrimidinyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine monotrifluoroacetate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

10/734039

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(drug candidate; preparation of pyrrolotriazines as HER1, HER2, and HER4  
kinase inhibitors, and antiproliferative agents)


RN 859851-53-9 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazin-4-amine, 5-[(4-amino-1-piperidinyl)methyl]-N-  
(4-methyl-2-pyrimidinyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 859851-52-8

CMF C17 H22 N8




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:572601 CAPLUS

DN 143:97354

TI Preparation of novel fused pyrrolocarbazoles for treating or preventing  
angiogenesis and angiogenic disorders

IN Hudkins, Robert L.; Zulli, Allison L.; Reddy, Dandu R.; Gingrich, Diane  
E.; Tao, Ming; Becknell, Nadine C.; Diebold, James L.; Underiner, Theodore  
L.

PA USA

SO U.S. Pat. Appl. Publ., 111 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2005143442	A1	20050630	US 2004-17947	20041222

WO 2005063763 A1 20050714 WO 2004-US43160 20041223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-532182P P 20031223  
 US 2004-17947 A 20041222

OS MARPAT 143:97354


IT 856691-95-7P 856691-97-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel fused pyrrolocarbazoles for treating or preventing angiogenesis and angiogenic disorders)


RN 856691-95-7 CAPLUS

CN 4H-Indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one, 2,5,6,11,12,13-hexahydro-8-[(4-methoxy-2-pyrimidinyl)amino]-2-methyl-11-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 856691-97-9 CAPLUS

CN 4H-Indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one, 2,5,6,11,12,13-hexahydro-2-methyl-11-(2-methylpropyl)-8-[[4-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



10/734039

AN 2005:569435 CAPLUS

DN 143:99063

TI Coloring compositions for use in ink-jet printing inks and ink-jet recording, color toners, optical recording media, thermal-transfer printing sheets, and color filters

IN Takahashi, Mari; Yasukawa, Hiroyuki; Suzuki, Takashi; Ikesu, Satoru

PA Konica Minolta Holdings, Inc., Japan

SO Jpn. Kokai Tokkyo Koho, 60 pp.

CODEN: JKXXAF

DT Patent

LA Japanese


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2005171079	A2	20050630	JP 2003-413032	20031211
PRAI	JP 2003-413032		20031211		
OS	MARPAT 143:99063				
IT	856413-15-5				

RL: TEM (Technical or engineered material use); USES (Uses)  
(azo dyes for color toners with good hue and lightfastness)

RN 856413-15-5 CAPLUS

CN Phenol, 2-[[2-[(5,6-dimethoxy-2-benzothiazolyl)amino]-4-methoxy-5-pyrimidinyl]azo]-4-(pentyloxy)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 856412-96-9 856413-10-0

RL: TEM (Technical or engineered material use); USES (Uses)  
(azo dyes for magenta ink-jet inks with good light and ozone resistance)

RN 856412-96-9 CAPLUS

CN Benzamide, N-[2-(2-benzothiazolylamino)-5-[(5-phenyl-1H-1,2,4-triazol-3-yl)azo]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 856413-10-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-[(1-ethyl-3-methyl-1H-indol-2-yl)azo]-N2-(6-methoxy-2-benzothiazolyl)-N4,N4-dimethyl- (9CI) (CA INDEX NAME)

10/734039



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 6 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:497492 CAPLUS

DN 143:7727

TI Preparation of 2,4-diaminopyrimidine derivatives as inhibitors of PKC-theta for treating diseases associated with T cells activation, in particular immunol. disorders and type II diabetes

IN Cardozo, Mario G.; Cogan, Derek; Cywin, Charles Lawrence; Dahmann, George; Disalvo, Darren; Ginn, John David; Prokopowicz, Anthony S.; Spero, Denise M.; Young, Erick Richard Roush

PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SO U.S. Pat. Appl. Publ., 69 pp., Cont.-in-part of U.S. Ser. No. 766,079. CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005124640	A1	20050609	US 2004-933635	20040903
	US 2004242613	A1	20041202	US 2004-766079	20040127
PRAI	US 2003-443700P	P	20030130		
	US 2004-766079	A2	20040127		

OS MARPAT 143:7727

IT 736051-05-1P 736051-54-0P 736052-30-5P

736052-41-8P 736052-46-3P 736052-50-9P

736052-76-9P 737756-40-0P 737756-41-1P

737756-42-2P 737756-43-3P 737756-49-9P


737756-50-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PKC-theta inhibitor; preparation of diaminopyrimidines as PKC-theta inhibitors for treating diseases associated with T cells activation, in particular immunol. disorders and type II diabetes)

RN 736051-05-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl)methyl]-N2-2-naphthalenyl-5-nitro- (9CI) (CA INDEX NAME)




RN 736051-54-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl)methyl]-N2-1-naphthalenyl-5-nitro- (9CI) (CA INDEX NAME)




10/734039




RN 736052-30-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-N2-(2,3-dihydro-1H-inden-2-yl)-5-nitro- (9CI) (CA INDEX NAME)




RN 736052-41-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-N2-(4-chloro-1-naphthalenyl)-5-nitro- (9CI) (CA INDEX NAME)



RN 736052-46-3 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-N2-(4-methoxy-2-naphthalenyl)-5-nitro- (9CI) (CA INDEX NAME)



RN 736052-50-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-5-nitro-N2-6-quinolinyl- (9CI) (CA INDEX NAME)

10/734039



RN 736052-76-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-5-bromo-N2-2-naphthalenyl- (9CI) (CA INDEX NAME)



RN 737756-40-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-5-nitro-N2-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737756-41-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-5-nitro-N2-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 737756-42-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-5-nitro-N2-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/734039



RN 737756-43-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-5-nitro-N2-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737756-49-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-N2-[(1S)-2,3-dihydro-1H-inden-1-yl]-5-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737756-50-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-N2-[(1R)-2,3-dihydro-1H-inden-1-yl]-5-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 7 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2005:324323 CAPLUS  
 DN 142:367631  
 TI Fluorescent probes for use in protein kinase inhibitor binding competition assay for screening applications  
 IN Prokopowicz, Anthony S.; Brown, Martha Priscilla; Wildeson, Jessi Marie; Jakes, Scott; Labadia, Mark E.  
 PA Boehringer Ingelheim Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 49 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005033330	A2	20050414	WO 2004-US32253	20040930
	WO 2005033330	A3	20050728		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005100978	A1	20050512	US 2004-955129	20040930
PRAI	US 2003-508539P	P	20031003		
OS	MARPAT 142:367631				
IT	849339-55-5				


RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (fluorescent probe; fluorescent probes for use in protein kinase inhibitor binding competition assay for screening applications)

RN 849339-55-5 CAPLUS

CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-5-carboxamide, 2',7'-difluoro-3',6'-dihydroxy-N-[6-[[2-(2-naphthalenylamino)-5-nitro-4-pyrimidinyl]amino]hexyl]-3-oxo- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2005:286338 CAPLUS  
 DN 143:7668  
 TI Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors  
 AU Verma, Sharad; Nagarathnam, Dhanapalan; Shao, Jianxing; Zhang, Lei; Zhao, Jin; Wang, Yamin; Li, Tindy; Mull, Eric; Enyedy, Istvan; Wang, Chunguang; Zhu, Qingming; Altieri, Martha; Jordan, Jerold; Dang, Thu-Thi-Anh; Reddy, Sanjeeva  
 CS Department of Chemistry Research, Bayer Research Center, West Haven, CT, 06516, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2005), 15(8), 1973-1977  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier B.V.  
 DT Journal  
 LA English  
 IT 852357-32-5P 852357-43-8P 852357-44-9P 852357-45-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (preparation and cyclin-dependent kinase binding affinity of (benzimidazolylamino)pyrimidines starting from dichloropyrimidines and aminobenzimidazoles using amination as the key step)  
 RN 852357-32-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-5-yl-5-bromo-N4-[(2,3-dichlorophenyl)methyl]-N4-methyl- (9CI) (CA INDEX NAME)




RN 852357-43-8 CAPLUS  
 CN 1H-Benzimidazol-5-amine, N-[4-ethoxy-5-(trifluoromethyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/734039




RN 852357-44-9 CAPLUS

CN 1H-Benzimidazol-5-amine, N-[4-(1-methylethoxy)-5-(trifluoromethyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 852357-45-0 CAPLUS

CN 1H-Benzimidazol-5-amine, N-[4-(2-methylpropoxy)-5-(trifluoromethyl)-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:283469 CAPLUS

DN 142:355174

TI Preparation of 1,4-disubstituted isoquinoline derivatives as RAF kinase inhibitors useful for the treatment of proliferative diseases

IN Fink, Cynthia Anne; Perez, Lawrence Blas; Ramsey, Timothy Michael; Yusuff, Naeem; Versace, Richard William; Batt, David Bryant; Sabio, Michael Lloyd; Kim, Sunkyu

PA Novartis Ag, Switz.; Novartis Pharma GmbH

SO PCT Int. Appl., 144 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005028444	A1	20050331	WO 2004-EP10688	20040923
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,			

10/734039

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
SN, TD, TG

PRAI US 2003-505457P P 20030924

OS MARPAT 142:355174


IT 848840-57-3P 848841-18-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of 1,4-disubstituted isoquinolines as RAF kinase inhibitors for  
treating proliferative diseases)

RN 848840-57-3 CAPLUS


CN [4,7'-Biisoquinolin]-1-amine, N-[4-methyl-5-(1-methylethenyl)-2-  
pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 848841-18-9 CAPLUS

CN [4,7'-Biisoquinolin]-1-amine, N-[4-methyl-5-(1-methylethyl)-2-pyrimidinyl]-  
(9CI) (CA INDEX NAME)




10/734039

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2005:158646 CAPLUS  
DN 142:254587  
TI Methods for treating or preventing autoimmune diseases with  
2,4-pyrimidinediamine compounds  
IN Rajinder, Singh; Ankush, Argade; Li, Hui; Bhamidipati, Somasekhar;  
Carroll, David; Sylvain, Catherine; Clough, Jeffrey; Keim, Holger  
PA Rigel Pharmaceuticals, Inc., USA  
SO PCT Int. Appl., 276 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016893	A2	20050224	WO 2004-US24716	20040730
	WO 2005016893	A3	20050609		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				
	US 2005209224	A1	20050922	US 2004-903870	20040730
	US 2005234049	A1	20051020	US 2004-903263	20040730
PRAI	US 2003-491641P	P	20030730		
	US 2003-531598P	P	20031219		
	US 2004-572246P	P	20040518		
OS	MARPAT 142:254587				
IT	841290-08-2P 841290-15-1P 844433-51-8P				
	844433-55-2P 844433-56-3P 845817-80-3P				
	845818-29-3P 845818-30-6P 845818-31-7P				
	845818-32-8P 845818-33-9P 845818-36-2P				
	845820-62-4P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU				
	(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES				
	(Uses)				
	(pyrimidinediamine compds. for treatment or prevention of autoimmune				
	diseases)				
RN	841290-08-2 CAPLUS				
CN	2-Benzofurancarboxylic acid, 5-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)methylamino]-5-fluoro-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)				






10/734039


RN 841290-15-1 CAPLUS

CN Glycine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[5-fluoro-2-(1H-indol-6-ylamino)-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 844433-51-8 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[4-[(3,5-dimethoxyphenyl)methylamino]-5-fluoro-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 844433-55-2 CAPLUS


CN 1H-Indole-2-carboxylic acid, 7-[[4-[(3,4-dimethoxyphenyl)methylamino]-5-fluoro-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 844433-56-3 CAPLUS


CN 1H-Indole-2-carboxylic acid, 7-[[5-fluoro-4-[(2-hydroxyethyl)amino]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

10/734039




RN 845817-80-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(3,4-dimethoxyphenyl)-5-fluoro-N2-1H-indol-6-yl-N4-methyl- (9CI) (CA INDEX NAME)




RN 845818-29-3 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[4-[(3-chloro-4-methoxyphenyl)methylamino]-5-fluoro-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 845818-30-6 CAPLUS


CN 2-Benzofurancarboxylic acid, 5-[[5-fluoro-4-[methyl[6-(1-methylethoxy)-3-pyridinyl]amino]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 845818-31-7 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(4-chloro-3-methoxyphenyl)-5-fluoro-N2-1H-indol-5-yl-N4-methyl- (9CI) (CA INDEX NAME)

10/734039




RN 845818-32-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chloro-3,5-dimethylphenyl)-5-fluoro-N2-1H-indol-5-yl-N4-methyl- (9CI) (CA INDEX NAME)




RN 845818-33-9 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[4-[(4-chloro-3,5-dimethylphenyl)methylamino]-5-fluoro-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 845818-36-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-chloro-3,5-dimethylphenyl)-5-fluoro-N2-1H-indol-6-yl-N4-methyl- (9CI) (CA INDEX NAME)



RN 845820-62-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-5-fluoro-N2-1H-indazol-6-yl- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2005:136565 CAPLUS  
 DN 142:212327  
 TI 2,4-pyrimidinediamine compounds and uses as antiproliferative agents  
 IN Argade, Ankush; Singh, Rajinder; Li, Hui; Carroll, David; Catalano, Susan  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 179 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005013996	A2	20050217	WO 2004-US25409	20040806
	WO 2005013996	A3	20050609		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005113398	A1	20050526	US 2004-913270	20040806
PRAI	US 2003-494008P	P	20030807		
	US 2004-572534P	P	20040518		
OS	MARPAT 142:212327				
IT	844433-50-7P 844433-51-8P 844433-52-9P 844433-55-2P 844433-56-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(pyrimidinediamine compds. and uses as antiproliferative agents for treatment of cancer)				
RN	844433-50-7 CAPLUS				
CN	2-Benzofurancarboxylic acid, 7-[[4-[(2,3-dihydro-1,4-benzodioxin-6-yl)methylamino]-5-fluoro-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)				

10/734039




RN 844433-51-8 CAPLUS

CN 2-Benzofurancarboxylic acid, 5-[[4-[(3,5-dimethoxyphenyl)methylamino]-5-fluoro-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 844433-52-9 CAPLUS


CN 1H-Indole-2-carboxamide, 7-[[4-[(3,5-dimethoxyphenyl)methylamino]-5-fluoro-2-pyrimidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)



RN 844433-55-2 CAPLUS


CN 1H-Indole-2-carboxylic acid, 7-[[4-[(3,4-dimethoxyphenyl)methylamino]-5-fluoro-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

10/734039



RN 844433-56-3 CAPLUS

CN 1H-Indole-2-carboxylic acid, 7-[[5-fluoro-4-[(2-hydroxyethyl)amino]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:120923 CAPLUS

DN 142:219300

TI 2,4-Pyrimidinediamines for use in the treatment or prevention of autoimmune diseases

IN Rajinder, Singh; Ankush, Argade; Li, Hui; Bhamidipati, Somasekhar; Carroll, David; Sylvain, Catherine; Clough, Jeffrey; Keim, Holger

PA Rigel Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 169 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012294	A1	20050210	WO 2004-US24920	20040730
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				

10/734039

SN, TD, TG  
US 2005209224 A1 20050922 US 2004-903870 20040730  
US 2005234049 A1 20051020 US 2004-903263 20040730  
PRAI US 2003-491641P P 20030730  
US 2003-531598P P 20031219  
US 2004-572246P P 20040518  
OS MARPAT 142:219300  
IT 841290-08-2P 841290-15-1P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(pyrimidinediamines for use in the treatment or prevention of  
autoimmune diseases)  
RN 841290-08-2 CAPLUS  
CN 2-Benzofurancarboxylic acid, 5-[[4-[(2,3-dihydro-1,4-benzodioxin-6-  
yl)methylamino]-5-fluoro-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA  
INDEX NAME)



RN 841290-15-1 CAPLUS  
CN Glycine, N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[5-fluoro-2-(1H-indol-6-  
ylamino)-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2005:99485 CAPLUS  
DN 142:198090  
TI Preparation of 2-aminopyrimidines and 2-aminopyridine-4-carbamates for use  
in the treatment of autoimmune diseases  
IN Buchanan, John L.; Elbaum, Daniel; Martin, Matthew W.; McGowan, David C.;  
Novak, Perry M.; Nunes, Joseph J.  
PA Amgen Inc., USA  
SO PCT Int. Appl., 267 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009978	A1	20050203	WO 2004-US23233	20040715
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005026914 A1 20050203 US 2004-891636 20040713  
 PRAI US 2003-490220P P 20030724  
 US 2004-891636 A 20040713

OS MARPAT 142:198090


IT 837422-41-0P, 2,6-Dimethylphenyl N-[2-[(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)amino]-4-pyrimidinyl][4-(methyloxy)phenyl]carbamate  
 837422-54-5P, 2,6-Dimethylphenyl N-[2-(1H-indazol-5-ylamino)-4-pyrimidinyl](2-naphthalenyl)carbamate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aminopyrimidines and pyridinecarbamates for use in treatment of autoimmune diseases)


RN 837422-41-0 CAPLUS

CN Carbamic acid, [2-[(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)amino]-4-pyrimidinyl](4-methoxyphenyl)-, 2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RN 837422-54-5 CAPLUS

CN Carbamic acid, [2-(1H-indazol-5-ylamino)-4-pyrimidinyl]-2-naphthalenyl-, 2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN


AN 2004:1127334 CAPLUS



10/734039

DN 142:74445  
TI Preparation of tetrahydrocarbazole derivatives as human papillomaviruses inhibitors  
IN Boggs, Sharon Davis; Gudmundsson, Kristjan S.; Richardson, Leah D'Aurora; Sebahar, Paul Richard  
PA Smithkline Beecham Corporation, USA  
SO PCT Int. Appl., 69 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110999	A1	20041223	WO 2004-US17660	20040607
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-477251P	P	20030610		
	US 2003-497823P	P	20030826		
OS	MARPAT 142:74445				
IT	812649-26-6P, 6-Chloro-N-(4-methylpyrimidin-2-yl)-2,3,4,9-tetrahydro-1H-carbazol-1-amine				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of tetrahydrocarbazole derivs. as human papilloma viruses inhibitors)				
RN	812649-26-6 CAPLUS				
CN	1H-Carbazol-1-amine, 6-chloro-2,3,4,9-tetrahydro-N-(4-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)				



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:965255 CAPLUS  
DN 141:410950  
TI Preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in the treatment of hypertension  
IN Bell, Andrew Simon; Brown, David Graham; Fox, David Nathan Abraham; Marsh, Ian Roger; Morrell, Andrew Ian; Palmer, Michael John; Winslow, Carol Ann

10/734039

PA Pfizer Limited, UK; Pfizer Inc.  
SO PCT Int. Appl., 279 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096810	A1	20041111	WO 2004-IB1433	20040422
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	NL 1026074	A1	20041101	NL 2004-1026074	20040428
	NL 1026074	C2	20050809		
	US 2005043325	A1	20050224	US 2004-834484	20040429
PRAI	GB 2003-9780	A	20030429		
	GB 2003-27748	A	20031128		
	US 2003-476678P	P	20030606		
	US 2004-538147P	P	20040120		

OS MARPAT 141:410950

IT 792969-19-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PDE5 inhibitor; preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in treatment of hypertension)

RN 792969-19-8 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 1-(2-ethoxyethyl)-3-methyl-5-[(3R)-3-methyl-1-piperazinyl]-N-(4-methyl-2-pyrimidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 792971-11-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of 5,7-diaminopyrazolo[4,3-d]pyrimidines as selective PDE5 inhibitors useful in treatment of hypertension)

RN 792971-11-0 CAPLUS

CN 1H-Pyrazolo[4,3-d]pyrimidin-7-amine, 5-chloro-1-(2-ethoxyethyl)-3-methyl-N-

10/734039

(4-methyl-2-pyrimidinyl) - (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:818717 CAPLUS  
DN 142:253108  
TI Synthesis, magnetic and spectral studies of some novel binuclear dioxomolybdenum(VI) chelates involving Schiff bases derived from sulpha drugs and 4-benzoyl-3-methyl-1-phenyl-2-pyrazolin-5-one  
AU Maurya, R. C.; Pandey, A.; Sutradhar, D.  
CS Coordination Chemistry Laboratory, Department of P. G. Studies and Research in Chemistry, R. D. University, Jabalpur, 482 001, India  
SO Indian Journal of Chemistry, Section A: Inorganic, Bio-inorganic, Physical, Theoretical & Analytical Chemistry (2004), 43A(4), 763-768  
CODEN: ICACEC; ISSN: 0376-4710  
PB National Institute of Science Communication  
DT Journal  
LA English  
IT 844842-20-2P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of binuclear dioxomolybdenum(VI) chelates involving Schiff bases derived from sulfa drugs and benzoyl-pyrazolinone)  
RN 844842-20-2 CAPLUS  
CN Molybdenum, bis[μ-[4-[[[(4,5-dihydro-3-methyl-5-oxo-1-phenyl-1H-pyrazol-4-yl)phenyl)methylene]amino-κN]-N-(4-methyl-2-pyrimidinyl)benzenesulfonamide-κO]]tetrahydroxytetraoxodi- (9CI)  
(CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:648512 CAPLUS  
DN 141:190795  
TI Preparation of 2,4-diaminopyrimidine derivatives as inhibitors of PKC-theta for treating diseases associated with T cells activation, in particular immunol. disorders and type II diabetes  
IN Cardozo, Mario G.; Cogan, Derek; Cywin, Charles Lawrence; Dahmann, Georg; Disalvo, Darren; Ginn, John David; Prokopowicz, Anthony S.; Spero, Denice M.; Young, Erick Richard Roush  
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA; Boehringer Ingelheim Pharma GmbH & Co. KG  
SO PCT Int. Appl., 124 pp.  
CODEN: PIXXD2

10/734039

DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004067516	A1	20040812	WO 2004-US2240	20040127
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	CA 2514612	AA	20040812	CA 2004-2514612	20040127
	EP 1590334	A1	20051102	EP 2004-705675	20040127
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2003-443700P	P	20030130		
	WO 2004-US2240	W	20040127		

OS MARPAT 141:190795


IT 736051-05-1P, N'-[[4-(Aminomethyl)cyclohexyl)methyl]-N-(2-naphthyl)-5-nitropyrimidine-2,4-diamine 736051-54-0P, N'-[[4-(Aminomethyl)cyclohexyl)methyl]-N-(1-naphthyl)-5-nitropyrimidine-2,4-diamine 736052-30-5P, N'-[[4-(Aminomethyl)cyclohexyl)methyl]-N-(2,3-dihydro-1H-inden-2-yl)-5-nitropyrimidine-2,4-diamine 736052-41-8P, N'-[[4-(Aminomethyl)cyclohexyl)methyl]-N-(4-chloro-1-naphthyl)-5-nitropyrimidine-2,4-diamine 736052-46-3P, N'-[[4-(Aminomethyl)cyclohexyl)methyl]-N-(4-methoxy-2-naphthyl)-5-nitropyrimidine-2,4-diamine 736052-50-9P, N'-[[4-(Aminomethyl)cyclohexyl)methyl]-5-nitro-N-quinolin-6-ylpyrimidine-2,4-diamine 736052-76-9P, N'-[[4-(Aminomethyl)cyclohexyl)methyl]-5-bromo-N-(2-naphthyl)pyrimidine-2,4-diamine 737756-40-0P, N'-[[4-(Aminomethyl)cyclohexyl)methyl]-5-nitro-N-((2R)-1,2,3,4-tetrahydronaphthalen-2-yl)pyrimidine-2,4-diamine 737756-41-1P, N'-[[4-(Aminomethyl)cyclohexyl)methyl]-5-nitro-N-((2S)-1,2,3,4-tetrahydronaphthalen-2-yl)pyrimidine-2,4-diamine 737756-42-2P, N'-[[4-(Aminomethyl)cyclohexyl)methyl]-5-nitro-N-((1R)-1,2,3,4-tetrahydronaphthalen-1-yl)pyrimidine-2,4-diamine 737756-43-3P, N'-[[4-(Aminomethyl)cyclohexyl)methyl]-5-nitro-N-((1S)-1,2,3,4-tetrahydronaphthalen-1-yl)pyrimidine-2,4-diamine 737756-49-9P, N'-[[4-(Aminomethyl)cyclohexyl)methyl]-N-((1S)-2,3-dihydro-1H-inden-1-yl)-5-nitropyrimidine-2,4-diamine 737756-50-2P, N'-[[4-(Aminomethyl)cyclohexyl)methyl]-N-((1R)-2,3-dihydro-1H-inden-1-yl)-5-nitropyrimidine-2,4-diamine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PKC-theta inhibitor; preparation of diaminopyrimidines as PKC-theta inhibitors for treating diseases associated with T cells activation, in particular immunol. disorders and type II diabetes)

RN 736051-05-1 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl)methyl]-N2-2-naphthalenyl-5-nitro- (9CI) (CA INDEX NAME)



RN 736051-54-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl)methyl]-N2-1-naphthalenyl-5-nitro- (9CI) (CA INDEX NAME)

10/734039




RN 736052-30-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-N2-(2,3-dihydro-1H-inden-2-yl)-5-nitro- (9CI) (CA INDEX NAME)




RN 736052-41-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-N2-(4-chloro-1-naphthalenyl)-5-nitro- (9CI) (CA INDEX NAME)



RN 736052-46-3 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-N2-(4-methoxy-2-naphthalenyl)-5-nitro- (9CI) (CA INDEX NAME)



RN 736052-50-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-5-nitro-N2-6-quinolinyl- (9CI) (CA INDEX NAME)

10/734039



RN 736052-76-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-5-bromo-N2-2-naphthalenyl- (9CI) (CA INDEX NAME)



RN 737756-40-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-5-nitro-N2-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737756-41-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-5-nitro-N2-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 737756-42-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-5-nitro-N2-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/734039



RN 737756-43-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-5-nitro-N2-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737756-49-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-N2-[(1S)-2,3-dihydro-1H-inden-1-yl]-5-nitro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 737756-50-2 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[[4-(aminomethyl)cyclohexyl]methyl]-N2-[(1R)-2,3-dihydro-1H-inden-1-yl]-5-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 18 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:606472 CAPLUS  
 DN 141:157141  
 TI Preparation of diazepinoindolones as CHK-1 kinase inhibitors.  
 IN Ninkovic, Sacha; Bennett, Michael John; Rui, Yuanjin; Wang, Fen; Benedict, Suzanne Pritchett; Teng, Min  
 PA Pfizer Inc., USA  
 SO PCT Int. Appl., 279 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004063198	A1	20040729	WO 2004-IB26	20040105
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	CA 2512683	AA	20040729	CA 2004-2512683	20040105
	EP 1585749	A1	20051019	EP 2004-700145	20040105
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2005075499	A1	20050407	US 2004-754171	20040109
	US 6967198	B2	20051122		
PRAI	US 2003-439396P	P	20030109		
	WO 2004-IB26	W	20040105		
OS	MARPAT 141:157141				
IT	731809-68-0P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of diazepinoindolones as CHK-1 kinase inhibitors)				
RN	731809-68-0 CAPLUS				
CN	6H-Pyrrolo[4,3,2-ef][2,3]benzodiazepin-6-one, 8-[[4-(dimethylamino)-2-pyrimidinyl]amino]-1,5-dihydro- (9CI) (CA INDEX NAME)				





L4 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:589247 CAPLUS  
DN 141:140463  
TI Preparation of heterocyclic compounds as selective phosphodiesterase V  
inhibitors  
IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei  
PA Japan  
SO U.S. Pat. Appl. Publ., 116 pp., Cont.-in-part of U.S. Ser. No. 258,545.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2004142930	A1	20040722	US 2003-699804	20031104
	JP 2002012587	A2	20020115	JP 2000-277652	20000913
	JP 3637961	B2	20050413		
	WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					

PRAI	US 2003229089	A1	20031211	US 2002-258545	20021025
	JP 2000-130371	A	20000428		
	JP 2000-277652	A	20000913		
	WO 2001-JP2034	W	20010315		
	US 2002-258545	A2	20021025		
	JP 1999-261852	A	19990916		


IT 372114-55-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as selective phosphodiesterase V inhibitors for treating various diseases due to functional disorders on cGMP-signaling)

RN 372114-55-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-  
[(2,3-dihydro-1H-inden-2-yl)amino]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX  
NAME)



10/734039

L4 ANSWER 20 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2004:550943 CAPLUS  
DN 141:106492  
TI Preparation of pyrimidine derivatives for the treatment of abnormal cell growth in cancer  
IN Kath, John Charles; Luzzio, Michael Joseph  
PA Pfizer Products Inc., USA  
SO PCT Int. Appl., 148 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056786	A2	20040708	WO 2003-IB6055	20031217
	WO 2004056786	A3	20041021		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004220177	A1	20041104	US 2003-734039	20031211
	CA 2510848	AA	20040708	CA 2003-2510848	20031217
	EP 1578732	A2	20050928	EP 2003-780443	20031217
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	NL 1025071	A1	20040622	NL 2003-1025071	20031218
	NL 1025071	C2	20041230		
PRAI	US 2002-435670P	P	20021220		
	WO 2003-IB6055	W	20031217		

OS MARPAT 141:106492

IT 719311-94-1P, 5-Fluoro-N-(1H-indazol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine 719311-95-2P, 5-(5-Bromo-4-phenethylaminopyrimidin-2-ylamino)-1,3-dihydroindol-2-one 719311-99-6P, 5-Bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N'-(4-trifluoromethylbenzyl)pyrimidine-2,4-diamine trifluoroacetate  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(intermediate; preparation of pyrimidine derivs. as selective inhibitors of non-receptor tyrosine kinase for treatment of abnormal cell growth, in particular cancers)

RN 719311-94-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-fluoro-N2-1H-indazol-5-yl-N4-(2-pyridinylmethyl)-(9CI) (CA INDEX NAME)



10/734039

RN 719311-95-2 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[(2-phenylethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719311-99-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-N4-[[4-(trifluoromethyl)phenyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719311-98-5


CMF C25 H22 Br F3 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 719311-97-4P, 4-[5-[5-Bromo-4-(4-trifluoromethylbenzylamino)pyrimidin-2-ylamino]-1H-indol-3-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 719312-07-9P, 4-[5-(4-Benzylamino-5-bromopyrimidin-2-ylamino)-1H-indol-3-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 719312-44-4P, 4-[5-(5-Bromo-4-phenethylaminopyrimidin-2-ylamino)-1H-indol-3-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 719312-82-0P, 4-[6-[[5-Bromo-4-[[2-(3-chlorophenyl)ethyl]amino]pyrimidin-2-yl]amino]-1H-indol-3-yl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 719313-04-9P, [[5-Bromo-2-[(2-oxo-2,3-dihydro-1H-indol-5-yl)amino]pyrimidin-4-yl]amino]acetic acid tert-butyl ester  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


10/734039

(Reactant or reagent)

(intermediate; preparation of pyrimidine derivs. as selective inhibitors of non-receptor tyrosine kinase for treatment of abnormal cell growth, in particular cancers)


RN 719311-97-4 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[5-[[5-bromo-4-[[[4-(trifluoromethyl)phenyl]methyl]amino]-2-pyrimidinyl]amino]-1H-indol-3-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 719312-07-9 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[5-[[5-bromo-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]-1H-indol-3-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 719312-44-4 CAPLUS


CN 1(2H)-Pyridinecarboxylic acid, 4-[5-[[5-bromo-4-[(2-phenylethyl)amino]-2-pyrimidinyl]amino]-1H-indol-3-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



10/734039


RN 719312-82-0 CAPLUS

CN 1(2H)-Pyridinecarboxylic acid, 4-[6-[[5-bromo-4-[[2-(3-chlorophenyl)ethyl]amino]-2-pyrimidinyl]amino]-1H-indol-3-yl]-3,6-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 719313-04-9 CAPLUS

CN Glycine, N-[5-bromo-2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 511246-59-6P, 5-Bromo-N-(1H-indazol-5-yl)-N'-(2-trifluoromethylbenzyl)pyrimidine-2,4-diamine 717906-37-1P, 5-[[4-[(Pyridin-2-ylmethyl)amino]-5-trifluoromethylpyrimidin-2-yl]amino]-1,3-dihydroindol-2-one 717906-38-2P, 5-[5-Trifluoromethyl-4-(2-trifluoromethylbenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one 717906-39-3P, 5-[[4-[(3-Methylpyridin-2-ylmethyl)amino]-5-trifluoromethylpyrimidin-2-yl]amino]-1,3-dihydroindol-2-one 717906-40-6P, 5-[[4-[(3-(Methanesulfonyl)benzyl)amino]-5-trifluoromethylpyrimidin-2-yl]amino]-1,3-dihydroindol-2-one 719311-98-5P, 5-Bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N'-(4-trifluoromethylbenzyl)pyrimidine-2,4-diamine 719312-03-5P, 5-Bromo-N'-[(pyridin-2-yl)methyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine 719312-05-7P, N'-Benzyl-5-bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine 719312-08-0P, 5-Bromo-N'-((1R)-1-phenylethyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine 719312-09-1P, 5-Bromo-N'-((1R)-1-phenylethyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine trifluoroacetate 719312-11-5P, 5-Bromo-N'-(1-phenylethyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine 719312-12-6P, 5-Bromo-N'-(1-phenylethyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine trifluoroacetate 719312-14-8P, 5-Bromo-N'-((1S)-1-phenylethyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine 719312-15-9P, 5-Bromo-N'-((1S)-1-phenylethyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine trifluoroacetate 719312-17-1P, 4-[[[5-Bromo-2-[[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]amino]pyrimidin-4-yl]amino]methyl]benzenesulfonamide 719312-19-3P, 5-Bromo-N'-(4-methoxybenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine 719312-20-6P, 5-Bromo-N'-(4-methoxybenzyl)-N-[3-(1,2,3,6-

tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
 trifluoroacetate **719312-21-7P**, 5-Bromo-N'-(4-fluorobenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719312-22-8P**, 5-Bromo-N'-(4-fluorobenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
 trifluoroacetate **719312-23-9P**, 5-Bromo-N'-(3-fluorobenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719312-24-0P**, 5-Bromo-N'-(3-fluorobenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
 trifluoroacetate **719312-25-1P**, 5-Bromo-N'-[(naphthalen-1-yl)methyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-26-2P**, 5-Bromo-N'-[(naphthalen-1-yl)methyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
 trifluoroacetate **719312-27-3P**, 5-Bromo-N'-(4-fluoro-3-trifluoromethylbenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-28-4P**, 5-Bromo-N'-(4-fluoro-3-(trifluoromethyl)benzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine trifluoroacetate **719312-29-5P**,  
 5-Bromo-N'-(3-fluoro-5-trifluoromethylbenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719312-30-8P**, 5-Bromo-N'-(3-fluoro-5-trifluoromethylbenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
 trifluoroacetate **719312-31-9P**, 5-Bromo-N'-(4-phenoxybenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719312-32-0P**, 5-Bromo-N'-(4-phenoxybenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
 trifluoroacetate **719312-33-1P**, 5-Bromo-N'-(3,4-difluorobenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719312-34-2P**, 5-Bromo-N'-(3,4-difluorobenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
 trifluoroacetate **719312-35-3P**, 5-Bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N'-(3-trifluoromethoxybenzyl)pyrimidine-2,4-diamine **719312-36-4P**, 5-Bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N'-(3-trifluoromethoxybenzyl)pyrimidine-2,4-diamine trifluoroacetate **719312-37-5P**,  
 5-Bromo-N'-(4-chlorobenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-38-6P**, 5-Bromo-N'-(4-chlorobenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine trifluoroacetate **719312-39-7P**,  
 5-Bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N'-thiophen-2-ylmethylpyrimidine-2,4-diamine **719312-40-0P**,  
 5-Bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N'-thiophen-2-ylmethylpyrimidine-2,4-diamine trifluoroacetate **719312-41-1P**,  
 5-Bromo-N'-[(furan-2-yl)methyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-42-2P**,  
 5-Bromo-N'-phenethyl-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-43-3P**, 5-Bromo-N'-phenethyl-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
 trifluoroacetate **719312-45-5P**, 5-Bromo-N'-[2-(pyridin-2-yl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-46-6P**, 5-Bromo-N'-[2-(pyridin-2-yl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
 trifluoroacetate **719312-48-8P**, 5-Bromo-N'-[2-(pyridin-4-yl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-49-9P**, 5-Bromo-N'-[2-(pyridin-4-yl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
 trifluoroacetate **719312-50-2P**, 5-Bromo-N'-[2-(pyridin-3-yl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-51-3P**, 5-Bromo-N'-[2-(pyridin-3-yl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
 trifluoroacetate **719312-52-4P**, 5-Bromo-N'-[2-(3-fluorophenyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-54-6P**, 5-Bromo-N'-[2-(4-

chlorophenyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-55-7P**, 5-Bromo-N'-[2-(4-chlorophenyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine trifluoroacetate **719312-56-8P**, 5-Bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N'-[2-(thiophen-2-yl)ethyl]pyrimidine-2,4-diamine **719312-57-9P**, 5-Bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N'-[2-(thiophen-2-yl)ethyl]pyrimidine-2,4-diamine trifluoroacetate **719312-58-0P**, 5-Bromo-N'-[2-(2-fluorophenyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine hydrochloride **719312-59-1P**, 5-Bromo-N'-[2-(2-chlorophenyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine hydrochloride **719312-60-4P**, 5-Bromo-N'-[2-(2-methoxyphenyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine hydrochloride **719312-61-5P**, N'-[2-(Benzodioxol-5-yl)ethyl]-5-bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine hydrochloride **719312-62-6P**, 5-Bromo-N'-(3-phenylpropyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-63-7P**, 5-Bromo-N'-(3-phenylpropyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine trifluoroacetate **719312-65-9P**, 5-Bromo-N'-[2-(methanesulfonyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-66-0P**, 5-Bromo-N'-[2-(methanesulfonyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine trifluoroacetate **719312-67-1P**, N'-Benzyl-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-69-3P**, N'-Benzyl-N'-methyl-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-70-6P**, N'-Methyl-N'-[2-(pyridin-2-yl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-73-9P**, 5-Bromo-N-[3-(piperidin-4-yl)-1H-indol-5-yl]-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine hydrochloride **719312-74-0P**, 5-Bromo-N-[1-(methanesulfonyl)-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine hydrochloride **719312-79-5P**, 5-Bromo-N'-[2-(3-chlorophenyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-81-9P**, 5-Bromo-N'-[2-(3-chlorophenyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine trifluoroacetate **719312-83-1P**, 5-[[5-Bromo-4-[[2-(4-methoxyphenyl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719312-85-3P**, 5-Bromo-N'-[2-(4-methoxyphenyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-86-4P**, 5-Bromo-N'-[2-(4-methoxyphenyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine trifluoroacetate **719312-87-5P**, 5-[[5-Bromo-4-[[2-(3-methoxyphenyl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719312-89-7P**, 5-Bromo-N'-[2-(3-methoxyphenyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719312-90-0P**, 5-Bromo-N'-[2-(3-methoxyphenyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine trifluoroacetate **719312-91-1P**, 5-[[5-Bromo-4-[[2-(o-tolyl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719312-93-3P**, 5-Bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N'-[2-(o-tolyl)ethyl]pyrimidine-2,4-diamine **719312-94-4P**, 5-Bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N'-[2-(o-tolyl)ethyl]pyrimidine-2,4-diamine trifluoroacetate **719312-95-5P**, 5-[[5-Bromo-4-[[2-(m-tolyl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719312-97-7P**, 5-Bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N'-[2-(m-tolyl)ethyl]pyrimidine-2,4-diamine **719312-98-8P**, 5-[[5-Bromo-4-[[2-(p-tolyl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719313-00-5P**, 5-Bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-

indol-5-yl]-N'-[2-(p-tolyl)ethyl]pyrimidine-2,4-diamine  
**719313-01-6P**, 5-Bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N'-[2-(p-tolyl)ethyl]pyrimidine-2,4-diamine trifluoroacetate  
**719313-02-7P**, [[5-Bromo-2-[(2-oxo-2,3-dihydro-1H-indol-5-yl)amino]pyrimidin-4-yl]amino]acetic acid **719313-06-1P**,  
5-[[5-Bromo-4-[[2-(3-trifluoromethylphenyl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719313-10-7P**,  
5-[[4-[[2-(Biphenyl-4-yl)ethyl]amino]-5-bromopyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719313-14-1P**, 5-[[5-Bromo-4-[[2-(3-fluorophenyl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one  
**719313-16-3P**, 5-[[5-Bromo-4-[[2-(2-chlorophenyl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719313-20-9P**,  
5-[[5-Bromo-4-[[2-(2-methoxyphenyl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719313-23-2P**, 5-[[5-Bromo-4-[[2-(4-fluorophenyl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one  
**719313-24-3P**, 5-[[5-Bromo-4-[[2-(4-chlorophenyl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719313-26-5P**,  
5-[[5-Bromo-4-[[2-(2-fluorophenyl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719313-28-7P**, 5-[5-Bromo-4-(3-phenyl-2-propenylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one  
**719313-31-2P**, 5-[[5-Bromo-4-[(thiophen-2-ylmethyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719313-33-4P**,  
6-[[5-Bromo-4-[(thiophen-2-ylmethyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719313-34-5P**, 5-[5-Bromo-4-(2,3-dimethylbenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one  
**719313-36-7P**, 6-[5-Bromo-4-(2,3-dimethylbenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719313-37-8P**,  
5-[5-Bromo-4-(2,5-dimethylbenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719313-39-0P**, 6-[5-Bromo-4-(2,5-dimethylbenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one  
**719313-40-3P**, 6-[5-Bromo-4-(2-fluorobenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719313-42-5P**,  
6-[[5-Bromo-4-[(2-trifluoromethoxybenzyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719313-44-7P**, 5-[[5-Bromo-4-[(3-trifluoromethoxybenzyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one  
**719313-46-9P**, 6-[[5-Bromo-4-[(3-trifluoromethoxybenzyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719313-47-0P**,  
5-[[5-Bromo-4-[(4-trifluoromethoxybenzyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719313-49-2P**, 6-[[5-Bromo-4-[(4-trifluoromethoxybenzyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one  
**719313-50-5P**, 6-[5-Bromo-4-(2-methoxybenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719313-52-7P**,  
6-[5-Bromo-4-(3-methoxybenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719313-54-9P**, 6-[5-Bromo-4-(3-trifluoromethylbenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719313-55-0P**,  
5-[[5-Bromo-4-[(thiazol-2-ylmethyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719313-57-2P**, 5-[[5-Bromo-4-[[5-(methanesulfonyl)thiophen-2-yl]methyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one  
**719313-60-7P**, 5-[5-Bromo-4-(2,3-difluorobenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719313-62-9P**, 6-[5-Bromo-4-(2,3-difluorobenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719313-63-0P**,  
5-[5-Bromo-4-(2,4-difluorobenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719313-65-2P**, 6-[5-Bromo-4-(2,4-difluorobenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one  
**719313-68-5P**, 5-Bromo-N'-(2-methylbenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719313-69-6P**, 5-Bromo-N'-(3-methylbenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719313-70-9P**, 5-Bromo-N'-(4-methylbenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719313-71-0P**, 5-Bromo-N'-(2-fluorobenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine



**719313-72-1P**, N'-[(Biphenyl-2-yl)methyl]-5-bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719313-73-2P**, N'-[(Biphenyl-3-yl)methyl]-5-bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719313-74-3P**, 5-Bromo-N'-(2-methoxybenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719313-75-4P**, 5-Bromo-N'-(3-methoxybenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719313-76-5P**, 3-[[[5-Bromo-2-[[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]amino]pyrimidin-4-yl]amino]methyl]-N-methylbenzamide  
**719313-77-6P**, 5-Bromo-N'-(2-chlorobenzyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719313-78-7P**, 5-Bromo-N'-[2-(2-fluorophenyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719313-79-8P**, 5-Bromo-N'-[2-(2-chlorophenyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719313-80-1P**, 5-Bromo-N'-[2-(2-methoxyphenyl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719313-81-2P**, N'-[2-(Benzodioxol-5-yl)ethyl]-5-bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719313-82-3P**, 5-[5-Bromo-4-(2-chlorobenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719313-83-4P**,  
 5-(4-Benzylamino-5-bromopyrimidin-2-ylamino)-1,3-dihydroindol-2-one  
**719313-84-5P**, 5-[5-Bromo-4-(1-phenylethylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719313-85-6P**,  
 5-[5-Bromo-4-(3-phenylpropylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one  
**719313-86-7P**, 5-Methyl-N'-[2-(pyridin-2-yl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine  
**719313-87-8P**, 5-Bromo-N-[3-(piperidin-4-yl)-1H-indol-5-yl]-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine **719313-88-9P**,  
 5-Bromo-N-[1-(methanesulfonyl)-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine  
**719313-90-3P**, 3-[4-[[2-(Pyridin-2-yl)ethyl]amino]-2-[[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]amino]pyrimidin-5-yl]acrylic acid ethyl ester **719313-91-4P**, 5-[[[5-Bromo-4-[[2-(3-chlorophenyl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one  
**719313-92-5P**, 6-[5-Chloro-4-(2-trifluoromethylbenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719313-93-6P**,  
 5-Chloro-N-(1-methyl-1H-indol-5-yl)-N'-(2-trifluoromethylbenzyl)pyrimidine-2,4-diamine **719313-94-7P**, 5-Chloro-N-(1H-indazol-5-yl)-N'-(2-trifluoromethylbenzyl)pyrimidine-2,4-diamine **719313-95-8P**,  
 5-Chloro-N-(1-methyl-1H-indol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine **719313-96-9P**, 6-[[[5-Chloro-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one  
**719313-97-0P**, 5-Chloro-N-(1H-indazol-6-yl)-N'-(2-trifluoromethylbenzyl)pyrimidine-2,4-diamine **719313-98-1P**,  
 5-Chloro-N-(1H-indazol-6-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine **719313-99-2P**, [5-[[[5-Bromo-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]indazol-1-yl]acetic acid tert-butyl ester **719314-00-8P**, [6-[[[5-Bromo-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]indazol-2-yl]acetic acid tert-butyl ester **719314-01-9P**, 6-[[[4-[(Pyridin-2-ylmethyl)amino]-5-trifluoromethylpyrimidin-2-yl]amino]-1,3-dihydroindol-2-one  
**719314-02-0P**, N-(1-Methyl-1H-indol-5-yl)-N'-[(pyridin-2-yl)methyl]-5-trifluoromethylpyrimidine-2,4-diamine **719314-03-1P**,  
 [6-[[[5-Bromo-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]indol-1-yl]acetic acid tert-butyl ester **719314-04-2P**,  
 N'-[(Pyridin-2-yl)methyl]-N-(quinolin-5-yl)-5-trifluoromethylpyrimidine-2,4-diamine **719314-05-3P**, 2-[6-[[[5-Bromo-4-[(pyridin-2-yl)methyl]amino]pyrimidin-2-yl]amino]indol-1-yl]-N-(2-methoxyethyl)acetamide **719314-06-4P**, 6-[[[5-Chloro-4-[(3-methylpyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719314-07-5P**, [6-[[[5-Bromo-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one

ylmethyl)amino]pyrimidin-2-yl]amino]indol-1-yl]acetic acid  
**719314-08-6P**, [6-[[5-Bromo-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]indazol-1-yl]acetic acid tert-butyl ester **719314-09-7P**, N-(1H-Indazol-6-yl)-N'-[(pyridin-2-yl)methyl]-5-trifluoromethylpyrimidine-2,4-diamine **719314-10-0P**, [5-[[5-Bromo-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]indol-1-yl]acetic acid tert-butyl ester **719314-11-1P**, [6-[[5-Bromo-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]indazol-1-yl]acetic acid **719314-12-2P**, [5-[[5-Bromo-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]indol-1-yl]acetic acid **719314-13-3P**, [5-[[5-Bromo-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]indazol-1-yl]acetic acid **719314-14-4P**, 5-[[5-Chloro-4-[(3-methylpyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719314-15-5P**, 5-[[5-Chloro-4-[[3-(methanesulfonyl)benzyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719314-16-6P**, 6-[5-Chloro-4-(3-methylbenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719314-17-7P**, 5-[5-Chloro-4-(2-fluorobenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719314-18-8P**, 6-[5-Chloro-4-(2-fluorobenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719314-19-9P**, 5-[5-Bromo-4-(2-methoxyethylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719314-20-2P**, 5-[5-Chloro-4-(3-methylbenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one **719314-21-3P**, 6-[[5-Chloro-4-[(4-methylpyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719314-22-4P**, 5-(4-Benzylamino-5-chloropyrimidin-2-ylamino)-1,3-dihydroindol-2-one **719314-23-5P**, 5-Bromo-N-(1H-indol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine **719314-24-6P**, 5-Bromo-N-(1H-indol-5-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine **719314-25-7P**, 5-Bromo-N-(1H-indol-4-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine **719314-26-8P**, 5-Bromo-N-(1H-indazol-5-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine **719314-27-9P**, 5-Bromo-N-(1H-indazol-6-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine **719314-28-0P**, 5-Bromo-N-(1H-indol-4-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine **719314-29-1P**, 5-Bromo-N-(1H-indazol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine **719314-30-4P**, N-(1H-Indol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine **719314-31-5P**, N-(1H-Indazol-6-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine **719314-32-6P**, N-(1H-Indol-5-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine **719314-33-7P**, N-(1H-Indazol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine **719314-34-8P**, N-(1H-Indazol-5-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine **719314-35-9P**, N-(1H-Indazol-6-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine **719314-36-0P**, 5-[[5-Bromo-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]-1,3-dihydrobenzimidazol-2-one **719314-37-1P**, 5-[[5-Bromo-4-[[2-(pyridin-2-yl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydrobenzimidazol-2-one **719314-38-2P**, 5-[[4-[(Pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]-1,3-dihydrobenzimidazol-2-one **719314-39-3P**, 5-[[4-[[2-(Pyridin-2-yl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydrobenzimidazol-2-one **719314-40-6P**, 5-Bromo-N-(1H-indazol-6-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine **719314-41-7P**, 5-[[5-Bromo-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719314-42-8P**, 5-[[5-Bromo-4-[[2-(pyridin-2-yl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719314-43-9P**, 5-[[4-[[2-(Pyridin-2-yl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719314-44-0P**, 5-Bromo-N-(2-methyl-1H-indol-5-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine **719314-45-1P**, N-(2-Methyl-1H-indol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine **719314-46-2P**, N-(1H-Indol-6-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine


719314-47-3P, 5-Bromo-N-(2-methyl-1H-indol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine 719314-48-4P, 5-Bromo-N-(1H-indol-6-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine 719314-49-5P, 5-Bromo-N-(1H-indol-6-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine 719314-50-8P, N-(1H-Benzimidazol-5-yl)-5-bromo-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine 719314-51-9P, N-(1H-Benzimidazol-5-yl)-5-bromo-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine 719314-53-1P, N-(1H-Benzimidazol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine 719314-54-2P, 5-Bromo-N-(2-methyl-1H-benzimidazol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine 719314-55-3P, N-(2-Methyl-1H-benzimidazol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine 719314-56-4P, 5-Bromo-N-(2-methyl-1H-benzimidazol-5-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine 719314-57-5P, 5-Bromo-N-(2,3-dihydro-1H-indol-5-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine 719314-58-6P, N-(2,3-Dihydro-1H-indol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine 719314-59-7P, 5-Bromo-N-(1-methyl-1H-indol-5-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine 719314-60-0P, N-(1-Methyl-1H-indol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine 719314-61-1P, 5-Bromo-N-(2,3-dihydro-1H-indol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine 719314-62-2P, 5-Bromo-N-(1-methyl-1H-indol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine 719314-63-3P, 5-Fluoro-N'-[(pyridin-2-yl)methyl]-N-(quinolin-6-yl)pyrimidine-2,4-diamine 719314-64-4P, 5-Bromo-N'-[(pyridin-2-yl)methyl]-N-(quinolin-6-yl)pyrimidine-2,4-diamine 719314-65-5P, 5-Bromo-N-(1H-indol-7-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine 719314-66-6P, 5-Bromo-N-(1H-indol-7-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine 719314-67-7P, 5-Bromo-N-(1H-indazol-4-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine 719314-68-8P, 6-[[5-Bromo-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one 719314-69-9P, 5-Bromo-N-(1H-indazol-4-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine 719314-70-2P, 5-Bromo-N'-[2-(pyridin-2-yl)ethyl]-N-(quinolin-6-yl)pyrimidine-2,4-diamine 719314-71-3P, 5-Bromo-N'-[(pyridin-2-yl)methyl]-N-(quinolin-5-yl)pyrimidine-2,4-diamine 719314-72-4P, 5-Bromo-N'-[2-(pyridin-2-yl)ethyl]-N-(quinolin-5-yl)pyrimidine-2,4-diamine 719314-73-5P, 6-[[5-Bromo-4-[[2-(pyridin-2-yl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one 719314-74-6P, 5-Bromo-N'-[(pyridin-2-yl)methyl]-N-(quinolin-8-yl)pyrimidine-2,4-diamine 719314-75-7P, 5-Bromo-N'-[2-(pyridin-2-yl)ethyl]-N-(quinolin-8-yl)pyrimidine-2,4-diamine 719314-76-8P, 5-[[5-Bromo-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]-1H-indole-2-carboxylic acid ethyl ester 719314-77-9P, 6-[5-Bromo-4-(2-trifluoromethylbenzylamino)pyrimidin-2-ylamino]-1,3-dihydroindol-2-one 719314-78-0P, 5-Bromo-N-(1H-indazol-6-yl)-N'-(2-trifluoromethylbenzyl)pyrimidine-2,4-diamine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as selective inhibitors of non-receptor tyrosine kinase for treatment of abnormal cell growth, in particular cancers)

RN 511246-59-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-5-yl-N4-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

10/734039




RN 717906-37-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(2-pyridinylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717906-38-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[5-(trifluoromethyl)-4-[[[2-(trifluoromethyl)phenyl]methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717906-39-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[3-methyl-2-pyridinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717906-40-6 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 719311-98-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-N4-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

10/734039




RN 719312-03-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(2-pyridinylmethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719312-05-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(phenylmethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719312-08-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(1R)-1-phenylethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/734039



RN 719312-09-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(1R)-1-phenylethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-08-0

CMF C25 H25 Br N6


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 719312-11-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(1-phenylethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

10/734039




RN 719312-12-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(1-phenylethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-11-5


CMF C25 H25 Br N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 719312-14-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(1S)-1-phenylethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/734039



RN 719312-15-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(1S)-1-phenylethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-14-8

CMF C25 H25 Br N6


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 719312-17-1 CAPLUS

CN Benzenesulfonamide, 4-[[[5-bromo-2-[[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]amino]-4-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




10/734039



RN 719312-19-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(4-methoxyphenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719312-20-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(4-methoxyphenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-19-3


CMF C25 H25 Br N6 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



10/734039

RN 719312-21-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(4-fluorophenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719312-22-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(4-fluorophenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-21-7


CMF C24 H22 Br F N6



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 719312-23-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3-fluorophenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

10/734039




RN 719312-24-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3-fluorophenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-23-9


CMF C24 H22 Br F N6



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 719312-25-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(1-naphthalenylmethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

10/734039




RN 719312-26-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(1-naphthalenylmethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-25-1


CMF C28 H25 Br N6



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 719312-27-3 CAPLUS

10/734039

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719312-28-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-27-3


CMF C25 H21 Br F4 N6



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 719312-29-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

10/734039




RN 719312-30-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[[3-fluoro-5-(trifluoromethyl)phenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-29-5


CMF C25 H21 Br F4 N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 719312-31-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(4-phenoxyphenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




10/734039

RN 719312-32-0 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(4-phenoxyphenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 719312-31-9  
CMF C30 H27 Br N6 O




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 719312-33-1 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3,4-difluorophenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719312-34-2 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3,4-difluorophenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-33-1  
CMF C24 H21 Br F2 N6


10/734039



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 719312-35-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-N4-[[3-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 719312-36-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-N4-[[3-(trifluoromethoxy)phenyl)methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 719312-35-3

CMF C25 H22 Br F3 N6 O




10/734039



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 719312-37-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(4-chlorophenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719312-38-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(4-chlorophenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-37-5

CMF C24 H22 Br Cl N6




10/734039

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 719312-39-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-N4-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 719312-40-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-N2-(2-thienylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-39-7

CMF C22 H21 Br N6 S




CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/734039




RN 719312-41-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(2-furanylmethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719312-42-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(2-phenylethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719312-43-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(2-phenylethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-42-2

CMF C25 H25 Br N6




10/734039

CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 719312-45-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(2-pyridinyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719312-46-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(2-pyridinyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-45-5

CMF C24 H24 Br N7




CM 2


CRN 76-05-1

CMF C2 H F3 O2

10/734039




RN 719312-48-8 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(4-pyridinyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719312-49-9 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(4-pyridinyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 719312-48-8  
CMF C24 H24 Br N7




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 719312-50-2 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(3-pyridinyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

10/734039




RN 719312-51-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(3-pyridinyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-50-2


CMF C24 H24 Br N7



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 719312-52-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(3-fluorophenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

10/734039



RN 719312-54-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(4-chlorophenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719312-55-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(4-chlorophenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-54-6


CMF C25 H24 Br Cl N6



CM 2

CRN 76-05-1


CMF C2 H F3 O2



10/734039

RN 719312-56-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-N4-[2-(2-thienyl)ethyl]- (9CI) (CA INDEX NAME)




RN 719312-57-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-N4-[2-(2-thienyl)ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-56-8


CMF C23 H23 Br N6 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 719312-58-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(2-fluorophenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, hydrochloride (9CI) (CA INDEX NAME)




10/734039



●x HCl

RN 719312-59-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(2-chlorophenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 719312-60-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(2-methoxyphenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 719312-61-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-(1,3-benzodioxol-5-yl)ethyl]-5-bromo-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, hydrochloride (9CI) (CA INDEX NAME)


10/734039



●x HCl

RN 719312-62-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(3-phenylpropyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719312-63-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(3-phenylpropyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-62-6

CMF C26 H27 Br N6




CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/734039



RN 719312-65-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(methylsulfonyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719312-66-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(methylsulfonyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-65-9


CMF C20 H23 Br N6 O2 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 719312-67-1 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(phenylmethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

10/734039




RN 719312-69-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-methyl-N4-(phenylmethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719312-70-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-methyl-N4-[2-(2-pyridinyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719312-73-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-(4-piperidinyl)-1H-indol-5-yl]-N4-[2-(2-pyridinyl)ethyl]-, hydrochloride (9CI) (CA INDEX NAME)


10/734039



●x HCl

RN 719312-74-0 CAPLUS


CN 1H-Indol-5-amine, N-[5-bromo-4-[[2-(2-pyridinyl)ethyl]amino]-2-pyrimidinyl]-1-(methylsulfonyl)-3-(1,2,3,6-tetrahydro-4-pyridinyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 719312-79-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(3-chlorophenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719312-81-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(3-chlorophenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


10/734039

CRN 719312-79-5  
CMF C25 H24 Br Cl N6




CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 719312-83-1 CAPLUS  
CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-(4-methoxyphenyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719312-85-3 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(4-methoxyphenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719312-86-4 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(4-methoxyphenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

10/734039

CM 1

CRN 719312-85-3


CMF C26 H27 Br N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 719312-87-5 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-(3-methoxyphenyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719312-89-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(3-methoxyphenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719312-90-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(3-methoxyphenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI)


10/734039

(CA INDEX NAME)

CM 1

CRN 719312-89-7


CMF C26 H27 Br N6 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 719312-91-1 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-(2-methylphenyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719312-93-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(2-methylphenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719312-94-4 CAPLUS




10/734039

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(2-methylphenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-93-3


CMF C26 H27 Br N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 719312-95-5 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-(3-methylphenyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719312-97-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(3-methylphenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



10/734039


RN 719312-98-8 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-(4-methylphenyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-00-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(4-methylphenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719313-01-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(4-methylphenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719313-00-5

CMF C26 H27 Br N6




CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/734039




RN 719313-02-7 CAPLUS

CN Glycine, N-[5-bromo-2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 719313-06-1 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-[3-(trifluoromethyl)phenyl]ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-10-7 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[(2-[1,1'-biphenyl]-4-ylethyl)amino]-5-bromo-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-14-1 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-(3-fluorophenyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-16-3 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-(2-chlorophenyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)


10/734039

pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-20-9 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-(2-methoxyphenyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-23-2 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-(4-fluorophenyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-24-3 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-(4-chlorophenyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-26-5 CAPLUS


CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-(2-fluorophenyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



10/734039


RN 719313-28-7 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[(3-phenyl-2-propenyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-31-2 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[(2-thienylmethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-33-4 CAPLUS

CN 2H-Indol-2-one, 6-[[5-bromo-4-[(2-thienylmethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-34-5 CAPLUS


CN 2H-Indol-2-one, 5-[[5-bromo-4-[[[(2,3-dimethylphenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-36-7 CAPLUS


CN 2H-Indol-2-one, 6-[[5-bromo-4-[[[(2,3-dimethylphenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/734039




RN 719313-37-8 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2,5-dimethylphenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-39-0 CAPLUS

CN 2H-Indol-2-one, 6-[[5-bromo-4-[[2,5-dimethylphenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-40-3 CAPLUS


CN 2H-Indol-2-one, 6-[[5-bromo-4-[[2-(trifluoromethoxy)phenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-42-5 CAPLUS


CN 2H-Indol-2-one, 6-[[5-bromo-4-[[2-(trifluoromethoxy)phenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/734039




RN 719313-44-7 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[[3-(trifluoromethoxy)phenyl]methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-46-9 CAPLUS

CN 2H-Indol-2-one, 6-[[5-bromo-4-[[[3-(trifluoromethoxy)phenyl]methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-47-0 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[[4-(trifluoromethoxy)phenyl]methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-49-2 CAPLUS

CN 2H-Indol-2-one, 6-[[5-bromo-4-[[[4-(trifluoromethoxy)phenyl]methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-50-5 CAPLUS

CN 2H-Indol-2-one, 6-[[5-bromo-4-[[[2-methoxyphenyl]methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)


10/734039

pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-52-7 CAPLUS

CN 2H-Indol-2-one, 6-[[5-bromo-4-[[3-methoxyphenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-54-9 CAPLUS

CN 2H-Indol-2-one, 6-[[5-bromo-4-[[3-(trifluoromethyl)phenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-55-0 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[(2-thiazolyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-57-2 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[5-(methylsulfonyl)-2-thienyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)






10/734039


RN 719313-60-7 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2,3-difluorophenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-62-9 CAPLUS

CN 2H-Indol-2-one, 6-[[5-bromo-4-[[2,3-difluorophenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-63-0 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2,4-difluorophenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-65-2 CAPLUS


CN 2H-Indol-2-one, 6-[[5-bromo-4-[[2,4-difluorophenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-68-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(2-methylphenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

10/734039




RN 719313-69-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3-methylphenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719313-70-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(4-methylphenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719313-71-0 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(2-fluorophenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719313-72-1 CAPLUS


CN 2,4-Pyrimidinediamine, N4-([1,1'-biphenyl]-2-ylmethyl)-5-bromo-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

10/734039




RN 719313-73-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-([1,1'-biphenyl]-3-ylmethyl)-5-bromo-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719313-74-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(2-methoxyphenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719313-75-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3-methoxyphenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719313-76-5 CAPLUS

CN Benzamide, 3-[[[5-bromo-2-[[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-


10/734039

yl]amino]-4-pyrimidinyl]amino]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 719313-77-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(2-chlorophenyl)methyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719313-78-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(2-fluorophenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719313-79-8 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(2-chlorophenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719313-80-1 CAPLUS


10/734039

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(2-methoxyphenyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719313-81-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-(1,3-benzodioxol-5-yl)ethyl]-5-bromo-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719313-82-3 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-(chlorophenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-83-4 CAPLUS


CN 2H-Indol-2-one, 5-[[5-bromo-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-84-5 CAPLUS


CN 2H-Indol-2-one, 5-[[5-bromo-4-[(1-phenylethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/734039




RN 719313-85-6 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[(3-phenylpropyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719313-86-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-methyl-N4-[2-(2-pyridinyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719313-87-8 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-(4-piperidinyl)-1H-indol-5-yl]-N4-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 719313-88-9 CAPLUS


CN 1H-Indol-5-amine, N-[5-bromo-4-[[2-(2-pyridinyl)ethyl]amino]-2-pyrimidinyl]-1-(methylsulfonyl)-3-(1,2,3,6-tetrahydro-4-pyridinyl)- (9CI) (CA INDEX NAME)

10/734039




RN 719313-90-3 CAPLUS

CN 2-Propenoic acid, 3-[4-[[2-(2-pyridinyl)ethyl]amino]-2-[[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]amino]-5-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 719313-91-4 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-(3-chlorophenyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-92-5 CAPLUS


CN 2H-Indol-2-one, 6-[[5-chloro-4-[[2-(trifluoromethyl)phenyl]methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-93-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-(1-methyl-1H-indol-5-yl)-N4-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

10/734039




RN 719313-94-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-1H-indazol-5-yl-N4-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 719313-95-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-(1-methyl-1H-indol-5-yl)-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 719313-96-9 CAPLUS

CN 2H-Indol-2-one, 6-[[5-chloro-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719313-97-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-1H-indazol-6-yl-N4-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)






10/734039


RN 719313-98-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-1H-indazol-6-yl-N4-(2-pyridinylmethyl)-(9CI) (CA INDEX NAME)




RN 719313-99-2 CAPLUS

CN 1H-Indazole-1-acetic acid, 5-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 719314-00-8 CAPLUS

CN 2H-Indazole-2-acetic acid, 6-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 719314-01-9 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-6-[[4-[(2-pyridinylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 719314-02-0 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(1-methyl-1H-indol-5-yl)-N4-(2-pyridinylmethyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/734039




RN 719314-03-1 CAPLUS

CN 1H-Indole-1-acetic acid, 6-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 719314-04-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(2-pyridinylmethyl)-N2-5-quinolinyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 719314-05-3 CAPLUS


CN 1H-Indole-1-acetamide, 6-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)



RN 719314-06-4 CAPLUS


CN 2H-Indol-2-one, 6-[[5-chloro-4-[(3-methyl-2-pyridinyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/734039




RN 719314-07-5 CAPLUS

CN 1H-Indole-1-acetic acid, 6-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 719314-08-6 CAPLUS

CN 1H-Indazole-1-acetic acid, 6-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 719314-09-7 CAPLUS


CN 2,4-Pyrimidinediamine, N2-1H-indazol-6-yl-N4-(2-pyridinylmethyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 719314-10-0 CAPLUS


CN 1H-Indole-1-acetic acid, 5-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/734039




RN 719314-11-1 CAPLUS

CN 1H-Indazole-1-acetic acid, 6-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 719314-12-2 CAPLUS

CN 1H-Indazole-1-acetic acid, 5-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 719314-13-3 CAPLUS


CN 1H-Indazole-1-acetic acid, 5-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 719314-14-4 CAPLUS


CN 2H-Indol-2-one, 5-[[5-chloro-4-[[[(3-methyl-2-pyridinyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro]- (9CI) (CA INDEX NAME)

10/734039




RN 719314-15-5 CAPLUS

CN 2H-Indol-2-one, 5-[[5-chloro-4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719314-16-6 CAPLUS

CN 2H-Indol-2-one, 6-[[5-chloro-4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719314-17-7 CAPLUS

CN 2H-Indol-2-one, 5-[[5-chloro-4-[[[2-(fluorophenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719314-18-8 CAPLUS


CN 2H-Indol-2-one, 6-[[5-chloro-4-[[[2-(fluorophenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719314-19-9 CAPLUS


10/734039

CN 2H-Indol-2-one, 5-[[5-bromo-4-[(2-methoxyethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719314-20-2 CAPLUS

CN 2H-Indol-2-one, 5-[[5-chloro-4-[[[(3-methylphenyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719314-21-3 CAPLUS

CN 2H-Indol-2-one, 6-[[5-chloro-4-[[[(4-methyl-2-pyridinyl)methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719314-22-4 CAPLUS


CN 2H-Indol-2-one, 5-[[5-chloro-4-[(phenylmethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719314-23-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indol-5-yl-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

10/734039




RN 719314-24-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indol-5-yl-N4-[2-(2-pyridinyl)ethyl]-  
(9CI) (CA INDEX NAME)




RN 719314-25-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indol-4-yl-N4-[2-(2-pyridinyl)ethyl]-  
(9CI) (CA INDEX NAME)



RN 719314-26-8 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-5-yl-N4-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 719314-27-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-6-yl-N4-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

10/734039




RN 719314-28-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indol-4-yl-N4-(2-pyridinylmethyl)-  
(9CI) (CA INDEX NAME)




RN 719314-29-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-5-yl-N4-(2-pyridinylmethyl)-  
(9CI) (CA INDEX NAME)



RN 719314-30-4 CAPLUS

CN 2,4-Pyrimidinediamine, N2-1H-indol-5-yl-N4-(2-pyridinylmethyl)- (9CI) (CA  
INDEX NAME)




RN 719314-31-5 CAPLUS


CN 2,4-Pyrimidinediamine, N2-1H-indazol-6-yl-N4-(2-pyridinylmethyl)- (9CI)  
(CA INDEX NAME)




10/734039




RN 719314-32-6 CAPLUS  
CN 2,4-Pyrimidinediamine, N2-1H-indol-5-yl-N4-[2-(2-pyridinyl)ethyl]- (9CI)  
(CA INDEX NAME)




RN 719314-33-7 CAPLUS  
CN 2,4-Pyrimidinediamine, N2-1H-indazol-5-yl-N4-(2-pyridinylmethyl)- (9CI)  
(CA INDEX NAME)



RN 719314-34-8 CAPLUS  
CN 2,4-Pyrimidinediamine, N2-1H-indazol-5-yl-N4-[2-(2-pyridinyl)ethyl]- (9CI)  
(CA INDEX NAME)




RN 719314-35-9 CAPLUS  
CN 2,4-Pyrimidinediamine, N2-1H-indazol-6-yl-N4-[2-(2-pyridinyl)ethyl]- (9CI)  
(CA INDEX NAME)




RN 719314-36-0 CAPLUS  
CN 2H-Benzimidazol-2-one, 5-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/734039




RN 719314-37-1 CAPLUS

CN 2H-Benzimidazol-2-one, 5-[[5-bromo-4-[[2-(2-pyridinyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719314-38-2 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[[4-[[2-(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 719314-39-3 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-5-[[4-[[2-(2-pyridinyl)ethyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 719314-40-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-6-yl-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 719314-41-7 CAPLUS


CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/734039




RN 719314-42-8 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[2-(2-pyridinyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719314-43-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[2-(2-pyridinyl)ethyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 719314-44-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-(2-methyl-1H-indol-5-yl)-N4-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 719314-45-1 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(2-methyl-1H-indol-5-yl)-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 719314-46-2 CAPLUS


CN 2,4-Pyrimidinediamine, N2-1H-indol-6-yl-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

10/734039




RN 719314-47-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-(2-methyl-1H-indol-5-yl)-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 719314-48-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indol-6-yl-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 719314-49-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indol-6-yl-N4-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 719314-50-8 CAPLUS

CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-5-yl-5-bromo-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 719314-51-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-5-yl-5-bromo-N4-[2-(2-


10/734039

pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 719314-53-1 CAPLUS

CN 2,4-Pyrimidinediamine, N2-1H-benzimidazol-5-yl-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 719314-54-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-(2-methyl-1H-benzimidazol-5-yl)-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 719314-55-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(2-methyl-1H-benzimidazol-5-yl)-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 719314-56-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-(2-methyl-1H-benzimidazol-5-yl)-N4-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 719314-57-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-(2,3-dihydro-1H-indol-5-yl)-N4-[2-(2-


10/734039

pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 719314-58-6 CAPLUS

CN 2,4-Pyrimidinediamine, N3-(2,3-dihydro-1H-indol-5-yl)-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 719314-59-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-(1-methyl-1H-indol-5-yl)-N4-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 719314-60-0 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(1-methyl-1H-indol-5-yl)-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 719314-61-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-(2,3-dihydro-1H-indol-5-yl)-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



10/734039


RN 719314-62-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-(1-methyl-1H-indol-5-yl)-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 719314-63-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N4-(2-pyridinylmethyl)-N2-6-quinolinyl- (9CI) (CA INDEX NAME)




RN 719314-64-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(2-pyridinylmethyl)-N2-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 719314-65-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indol-7-yl-N4-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 719314-66-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indol-7-yl-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

10/734039




RN 719314-67-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-4-yl-N4-(2-pyridinylmethyl)-  
(9CI) (CA INDEX NAME)



RN 719314-68-8 CAPLUS

CN 2H-Indol-2-one, 6-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-  
pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719314-69-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-4-yl-N4-[2-(2-  
pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




10/734039




RN 719314-70-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(2-pyridinyl)ethyl]-N2-6-quinolinyl-  
(9CI) (CA INDEX NAME)



RN 719314-71-3 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(2-pyridinylmethyl)-N2-5-quinolinyl-  
(9CI) (CA INDEX NAME)



RN 719314-72-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(2-pyridinyl)ethyl]-N2-5-quinolinyl-  
(9CI) (CA INDEX NAME)

10/734039




RN 719314-73-5 CAPLUS

CN 2H-Indol-2-one, 6-[[5-bromo-4-[[2-(2-pyridinyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719314-74-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(2-pyridinylmethyl)-N2-8-quinolinyl- (9CI) (CA INDEX NAME)



RN 719314-75-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(2-pyridinyl)ethyl]-N2-8-quinolinyl- (9CI) (CA INDEX NAME)

10/734039




RN 719314-76-8 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 719314-77-9 CAPLUS

CN 2H-Indol-2-one, 6-[[5-bromo-4-[[[2-(trifluoromethyl)phenyl]methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719314-78-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-6-yl-N4-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



IT 719314-79-1P, 5-Bromo-N-(1-methyl-1H-indol-5-yl)-N'-(2-trifluoromethylbenzyl)pyrimidine-2,4-diamine 719314-80-4P, 5-Bromo-N-(1H-indazol-7-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine 719314-81-5P, 5-Bromo-N-(1H-indazol-4-yl)-N'-(2-trifluoromethylbenzyl)pyrimidine-2,4-diamine 719314-82-6P, 6-[[5-Bromo-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]-3H-isobenzofuran-1-one 719314-83-7P, N-(Benzothiazol-6-yl)-5-bromo-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine 719314-84-8P, 5-[[5-Bromo-4-[(pyridin-2-ylmethyl)amino]pyrimidin-2-yl]amino]-2-methyl-1H-

indole-3-carbonitrile **719314-85-9P**, 5-Bromo-N'-[(pyridin-2-yl)methyl]-N-[1-[(pyridin-2-yl)methyl]-1H-indazol-5-yl]pyrimidine-2,4-diamine **719314-86-0P**, N-(1-Benzyl-1H-indol-5-yl)-5-bromo-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine **719314-87-1P**, 5-Bromo-N'-[(pyridin-2-yl)methyl]-N-[1-[(pyridin-2-yl)methyl]-1H-indol-5-yl]pyrimidine-2,4-diamine **719314-88-2P**, N-(1-Benzyl-1H-indazol-5-yl)-5-bromo-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine **719314-89-3P**, 5-Bromo-N-(1-methyl-1H-indazol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine **719314-91-7P**, 5-Bromo-N'-(cyclohexylmethyl)-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719314-94-0P**, 5-[[5-Fluoro-4-[(pyridin-2-yl)methyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719314-95-1P**, 5-Chloro-N-(1H-indazol-5-yl)-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine **719314-96-2P**, 5-[[5-Chloro-4-[(pyridin-2-yl)methyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719314-97-3P**, 5-Fluoro-N'-[2-(pyridin-2-yl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719314-98-4P**, 5-Chloro-N'-[2-(pyridin-2-yl)ethyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719314-99-5P**, 5-Fluoro-N-(1H-indazol-5-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine **719315-00-1P**, 5-[[5-Fluoro-4-[2-(pyridin-2-yl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-01-2P**, 5-Chloro-N-(1H-indazol-5-yl)-N'-[2-(pyridin-2-yl)ethyl]pyrimidine-2,4-diamine **719315-02-3P**, 5-[[5-Chloro-4-[2-(pyridin-2-yl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-03-4P**, 5-[[5-Methoxy-4-[(pyridin-2-yl)methyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-04-5P**, 5-[[5-Methoxy-4-[2-(pyridin-2-yl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-05-6P**, 5-[[5-Methoxy-4-(2-trifluoromethylbenzylamino)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-06-7P**, 5-[[5-Bromo-4-[(cyclohex-1-enyl)methyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-07-8P**, 5-[[5-Bromo-4-[methyl(pyridin-2-yl)methyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-09-0P**, 5-[[5-Bromo-4-[(cyclohexylmethyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-10-3P**, 5-[[5-Chloro-4-(2-trifluoromethylbenzylamino)pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-11-4P**, 2-[(2-Oxo-2,3-dihydro-1H-indol-5-yl)amino]-4-[[pyridin-2-yl)methyl]amino]pyrimidine-5-carbonitrile **719315-12-5P**, 5-[[5-Methyl-4-[(pyridin-2-yl)methyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-13-6P**, N-(1H-Indazol-5-yl)-5-methyl-N'-[(pyridin-2-yl)methyl]pyrimidine-2,4-diamine **719315-14-7P**, 5-Fluoro-N'-[(pyridin-2-yl)methyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719315-15-8P**, 5-Chloro-N'-[(pyridin-2-yl)methyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719315-16-9P**, 2-[(2-Oxo-2,3-dihydro-1H-indol-5-yl)amino]-4-(2-trifluoromethylbenzylamino)pyrimidine-5-carbonitrile **719315-17-0P**, 5-[[4-[Methyl[2-(pyridin-2-yl)ethyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-18-1P**, 5-Bromo-N'-[(cyclohex-1-enyl)methyl]-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine **719315-19-2P**, N-(1H-Indazol-5-yl)-N'-[(pyridin-2-yl)methyl]-5-trifluoromethylpyrimidine-2,4-diamine **719315-23-8P**, 2-[(2-Oxo-2,3-dihydro-1H-indol-6-yl)amino]-4-[[pyridin-2-yl)methyl]amino]pyrimidine-5-carbonitrile **719315-24-9P**, 6-[[4-[(3-Methylpyridin-2-yl)methyl]amino]-5-trifluoromethylpyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-31-8P**, 6-[[4-[(3-(Methanesulfonyl)benzyl]amino]-5-methoxypyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-32-9P**, 6-[[4-[(3-(Methanesulfonyl)benzyl]amino)-5-trifluoromethylpyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-33-0P**, 6-[[4-[(3-(Methanesulfonyl)benzyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-35-2P**, 6-[[5-Chloro-4-(piperidin-3-


ylmethyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one  
**719315-36-3P**, 6-[[[5-Chloro-4-[[[1-(methanesulfonyl)piperidin-3-yl]methyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one  
**719315-37-4P**, 6-[[[5-Bromo-4-[(piperidin-3-ylmethyl)amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-38-5P**,  
 6-[[[5-Bromo-4-[[[1-(methanesulfonyl)piperidin-3-yl]methyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-39-6P**,  
 5-[[[5-Fluoro-4-[[3-(methanesulfonyl)benzyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one **719315-40-9P**, 5-[[[5-Bromo-4-[[[1-hydroxycyclohexyl)methyl]amino]pyrimidin-2-yl]amino]-1,3-dihydroindol-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as selective inhibitors of non-receptor tyrosine kinase for treatment of abnormal cell growth, in particular cancers)


RN 719314-79-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-(1-methyl-1H-indol-5-yl)-N4-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 719314-80-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-7-yl-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 719314-81-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-4-yl-N4-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

10/734039




RN 719314-82-6 CAPLUS

CN 1(3H)-Isobenzofuranone, 6-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 719314-83-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-6-benzothiazolyl-5-bromo-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 719314-84-8 CAPLUS


CN 1H-Indole-3-carbonitrile, 5-[[5-bromo-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 719314-85-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(2-pyridinylmethyl)-N2-[1-(2-pyridinylmethyl)-1H-indazol-5-yl]- (9CI) (CA INDEX NAME)

10/734039




RN 719314-86-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[1-(phenylmethyl)-1H-indol-5-yl]-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 719314-87-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(2-pyridinylmethyl)-N2-[1-(2-pyridinylmethyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719314-88-2 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[1-(phenylmethyl)-1H-indazol-5-yl]-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 719314-89-3 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-(1-methyl-1H-indazol-5-yl)-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

10/734039




RN 719314-91-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(cyclohexylmethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719314-94-0 CAPLUS

CN 2H-Indol-2-one, 5-[[5-fluoro-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719314-95-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-1H-indazol-5-yl-N4-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 719314-96-2 CAPLUS

CN 2H-Indol-2-one, 5-[[5-chloro-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)






10/734039


RN 719314-97-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N4-[2-(2-pyridinyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719314-98-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[2-(2-pyridinyl)ethyl]-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719314-99-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N2-1H-indazol-5-yl-N4-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 719315-00-1 CAPLUS


CN 2H-Indol-2-one, 5-[[5-fluoro-4-[[2-(2-pyridinyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719315-01-2 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-1H-indazol-5-yl-N4-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

10/734039




RN 719315-02-3 CAPLUS

CN 2H-Indol-2-one, 5-[[5-chloro-4-[[2-(2-pyridinyl)ethyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719315-03-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[5-methoxy-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 719315-04-5 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[5-methoxy-4-[[2-(2-pyridinyl)ethyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 719315-05-6 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[5-methoxy-4-[[[2-(trifluoromethyl)phenyl]methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 719315-06-7 CAPLUS


CN 2H-Indol-2-one, 5-[[5-bromo-4-[(1-cyclohexen-1-ylmethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/734039




RN 719315-07-8 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[(methyl(2-pyridinylmethyl)amino)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719315-09-0 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[(cyclohexylmethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719315-10-3 CAPLUS

CN 2H-Indol-2-one, 5-[[5-chloro-4-[[[2-(trifluoromethyl)phenyl]methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719315-11-4 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-4-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 719315-12-5 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[5-methyl-4-[(2-pyridinylmethyl)amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/734039




RN 719315-13-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-1H-indazol-5-yl-5-methyl-N4-(2-pyridinylmethyl)-  
(9CI) (CA INDEX NAME)




RN 719315-14-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N4-(2-pyridinylmethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719315-15-8 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-(2-pyridinylmethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



RN 719315-16-9 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-4-[[[2-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

10/734039




RN 719315-17-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[methyl[2-(2-pyridinyl)ethyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 719315-18-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(1-cyclohexen-1-ylmethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




RN 719315-19-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-1H-indazol-5-yl-N4-(2-pyridinylmethyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 719315-23-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-2-oxo-1H-indol-6-yl)amino]-4-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 719315-24-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-[[4-[[[(3-methyl-2-pyridinyl)methyl]amino]-5-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


10/734039

(trifluoromethyl)-2-pyrimidinyl]amino] - (9CI) (CA INDEX NAME)




RN 719315-31-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-[[5-methoxy-4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-2-pyrimidinyl]amino] - (9CI) (CA INDEX NAME)




RN 719315-32-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino] - (9CI) (CA INDEX NAME)




RN 719315-33-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-2-pyrimidinyl]amino] - (9CI) (CA INDEX NAME)



RN 719315-35-2 CAPLUS


CN 2H-Indol-2-one, 6-[[5-chloro-4-[(3-piperidinylmethyl)amino]-2-pyrimidinyl]amino] - (9CI) (CA INDEX NAME)



10/734039


RN 719315-36-3 CAPLUS

CN 3-Piperidinemethanamine, N-[5-chloro-2-[(2,3-dihydro-2-oxo-1H-indol-6-yl)amino]-4-pyrimidinyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 719315-37-4 CAPLUS

CN 2H-Indol-2-one, 6-[[5-bromo-4-[(3-piperidinylmethyl)amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 719315-38-5 CAPLUS

CN 3-Piperidinemethanamine, N-[5-bromo-2-[(2,3-dihydro-2-oxo-1H-indol-6-yl)amino]-4-pyrimidinyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 719315-39-6 CAPLUS


CN 2H-Indol-2-one, 5-[[5-fluoro-4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 719315-40-9 CAPLUS

CN 2H-Indol-2-one, 5-[[5-bromo-4-[[[1-hydroxycyclohexyl]methyl]amino]-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/734039



IT 719312-68-2, N'-Benzyl-5-bromo-N-[3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]pyrimidine-2,4-diamine trifluoroacetate

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of pyrimidine derivs. as selective inhibitors of non-receptor tyrosine kinase for treatment of abnormal cell growth, in particular cancers)


RN 719312-68-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(phenylmethyl)-N2-[3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indol-5-yl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 719312-05-7


CMF C24 H23 Br N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2



L4 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:546498 CAPLUS

DN 141:106485

TI Preparation of pyrimidine derivatives for treatment of abnormal cell growth

IN Kath, John Charles; Luzzio, Michael Joseph

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004056807	A1	20040708	WO 2003-IB5883	20031208
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005009853	A1	20050113	US 2003-733215	20031211
	NL 1025067	A1	20040622	NL 2003-1025067	20031218
	NL 1025067	C2	20050215		
PRAI	US 2002-435670P	P	20021220		
	US 2003-500742P	P	20030905		
OS	MARPAT 141:106485				
IT	717905-10-7P	717905-11-8P	717905-12-9P		
	717905-13-0P	717905-14-1P	717905-15-2P		
	717905-16-3P	717905-17-4P	717905-18-5P		
	717905-19-6P	717905-20-9P	717905-21-0P		
	717905-22-1P	717905-23-2P	717905-24-3P		
	717905-25-4P	717905-26-5P	717905-27-6P		
	717905-28-7P	717905-29-8P	717905-30-1P		
	717905-31-2P	717905-32-3P	717905-33-4P		
	717905-34-5P	717905-35-6P	717905-36-7P		
	717905-37-8P	717905-38-9P	717905-39-0P		
	717905-40-3P	717905-41-4P	717905-42-5P		
	717905-43-6P	717905-44-7P	717905-45-8P		
	717905-46-9P	717905-47-0P	717905-48-1P		
	717905-49-2P	717905-50-5P	717905-51-6P		
	717905-52-7P	717905-53-8P	717905-54-9P		
	717905-55-0P	717905-56-1P	717905-57-2P		
	717905-58-3P	717905-59-4P	717905-60-7P		
	717905-61-8P	717905-62-9P	717905-63-0P		
	717905-64-1P	717905-65-2P	717905-66-3P		
	717905-67-4P	717905-68-5P	717905-69-6P		
	717905-70-9P	717905-71-0P	717905-72-1P		
	717905-73-2P	717905-74-3P	717905-75-4P		
	717905-76-5P	717905-77-6P	717905-78-7P		
	717905-79-8P	717905-80-1P	717905-81-2P		
	717905-82-3P	717905-83-4P	717905-84-5P		
	717905-85-6P	717905-86-7P	717905-87-8P		
	717905-88-9P	717905-89-0P	717905-90-3P		
	717905-91-4P	717905-93-6P	717905-94-7P		
	717905-95-8P	717905-96-9P	717905-97-0P		
	717905-98-1P	717905-99-2P	717906-02-0P		
	717906-03-1P	717906-04-2P	717906-05-3P		
	717906-06-4P	717906-07-5P	717906-08-6P		
	717906-09-7P	717906-10-0P	717906-11-1P		
	717906-12-2P	717906-13-3P	717906-14-4P		
	717906-15-5P	717906-16-6P	717906-17-7P		
	717906-18-8P	717906-19-9P	717906-20-2P		
	717906-21-3P	717906-22-4P	717906-23-5P		
	717906-24-6P	717906-25-7P	717906-26-8P		
	717906-27-9P	717906-28-0P	717906-29-1P		
	717906-30-4P	717906-31-5P	717906-32-6P		
	717906-34-8P	717906-35-9P	717906-36-0P		
	717906-37-1P	717906-38-2P	717906-39-3P		
	717906-40-6P	717906-41-7P	717906-42-8P		
	717906-43-9P	717906-44-0P	717906-45-1P		

717906-46-2P 717906-47-3P 717906-48-4P  
 717906-49-5P 717906-50-8P 717906-51-9P  
 717906-52-0P 717906-53-1P 717906-54-2P  
 717906-55-3P 717906-57-5P 717906-58-6P  
 717906-59-7P 717906-60-0P 717906-61-1P  
 717906-62-2P 717906-63-3P 717906-64-4P  
 717906-65-5P 717906-66-6P 717906-67-7P  
 717906-68-8P 717906-69-9P 717906-70-2P  
 717906-71-3P 717906-72-4P 717906-73-5P  
 717906-74-6P 717906-75-7P 717906-76-8P  
 717906-77-9P 717906-78-0P 717906-79-1P  
 717906-80-4P 717906-81-5P 717906-84-8P  
 717906-85-9P 717906-86-0P 717906-87-1P  
 717906-88-2P 717906-89-3P 717906-92-8P  
 717906-93-9P 717906-94-0P 717906-95-1P  
 717906-96-2P 717907-01-2P 717907-03-4P  
 717907-05-6P 717907-07-8P 717907-09-0P  
 717907-11-4P 717907-13-6P 717907-15-8P  
 717907-18-1P 717907-20-5P 717907-24-9P  
 717907-26-1P 717907-30-7P 717907-32-9P  
 717907-34-1P 717907-36-3P 717907-38-5P  
 717907-40-9P 717907-42-1P 717907-44-3P  
 717907-45-4P 717907-46-5P 717907-47-6P  
 717907-49-8P 717907-50-1P 717907-51-2P  
 717907-52-3P 717907-53-4P 717907-54-5P  
 717907-55-6P 717907-56-7P 717907-57-8P  
 717907-58-9P 717907-59-0P 717907-60-3P  
 717907-61-4P 717907-62-5P 717907-63-6P  
 717907-64-7P 717907-65-8P 717907-66-9P  
 717907-67-0P 717907-68-1P 717907-69-2P  
 717907-70-5P 717907-71-6P 717907-73-8P  
 717907-74-9P 717907-75-0P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. for treatment of abnormal cell growth)

RN 717905-10-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(1R)-1-phenylethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 717905-11-8 CAPLUS


CN Benzenesulfonamide, 3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-N-(1-methyl-1-phenylethyl)- (9CI) (CA INDEX NAME)

10/734039




RN 717905-12-9 CAPLUS

CN Benzenesulfonamide, 3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 717905-13-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[[5-(trifluoromethyl)-4-[[[3-[(trifluoromethyl)sulfonyl]phenyl]methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717905-14-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[[4-[(3-piperidinylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-15-2 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[[4-[[[1-(methanesulfonyl)-3-piperidinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



10/734039


RN 717905-16-3 CAPLUS

CN Methanesulfonamide, N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 717905-17-4 CAPLUS

CN Piperidine, 1-(cyanoacetyl)-3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 717905-18-5 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[[3-(1,1-dioxido-2-isothiazolidinyl)propyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717905-19-6 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(2-methylbutyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-20-9 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[1-(methanesulfonyl)-2-piperidinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/734039




RN 717905-21-0 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 717905-22-1 CAPLUS

CN Methanesulfonamide, N-[4-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]butyl]- (9CI) (CA INDEX NAME)



RN 717905-23-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[1-(methanesulfonyl)-4-piperidinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717905-24-3 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-N-methyl- (9CI) (CA INDEX NAME)


10/734039

NAME)




RN 717905-25-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[3-[(methanesulfonyl)oxy]phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717905-26-5 CAPLUS

CN Methanesulfonamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 717905-27-6 CAPLUS


CN Methanesulfonamide, N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)



10/734039


RN 717905-28-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(6-oxo-2-morpholinyl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717905-29-8 CAPLUS

CN Methanesulfonamide, N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 717905-30-1 CAPLUS

CN Methanesulfonamide, N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-4-methylphenyl]- (9CI) (CA INDEX NAME)



RN 717905-31-2 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[3-[(methanesulfonyl)methyl]phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



10/734039


RN 717905-32-3 CAPLUS

CN 2-Morpholinemethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-4-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 717905-33-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[1-(methylsulfonyl)-3-azetidiny]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-34-5 CAPLUS

CN Methanesulfonamide, N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-4-methylphenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 717905-35-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[1-(methylsulfonyl)-3-pyrrolidinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




10/734039




RN 717905-36-7 CAPLUS

CN Methanesulfonamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 717905-37-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[2-[1-(methanesulfonyl)-2-piperidinyl]ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-38-9 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[4-(methanesulfonyl)-2-pyridinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-39-0 CAPLUS


CN Carbamic acid, [3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]-2,2-dimethylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/734039




RN 717905-40-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[3-(1-methylethoxy)propyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717905-41-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(1-methyl-3-piperidiny]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-42-5 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(tetrahydro-2H-pyran-4-yl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-43-6 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[(2-ethylbutyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)


10/734039



RN 717905-44-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(2R)-tetrahydro-2-furanyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 717905-45-8 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 717905-46-9 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(5-methyl-2-furanyl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino] - (9CI) (CA INDEX NAME)



RN 717905-47-0 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[1-(methylsulfonyl)-2-pyrrolidinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino] - (9CI) (CA INDEX NAME)

10/734039




RN 717905-48-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(tricyclo[3.3.1.1<sup>3,7</sup>]dec-2-ylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-49-2 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(2-methoxy-2-methylpropyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-50-5 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[[1,3-dihydro-2H-indol-5-yl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 717905-51-6 CAPLUS


CN Phosphonic acid, [[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)

10/734039




RN 717905-52-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(3-methylbutyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717905-53-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(2-hydroxycyclohexyl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-54-9 CAPLUS


CN Methanesulfonamide, N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-4-methoxyphenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 717905-55-0 CAPLUS


CN 2-Morpholinemethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-4-(ethylsulfonyl)- (9CI) (CA INDEX NAME)

10/734039




RN 717905-56-1 CAPLUS

CN 2-Morpholinemethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-4-[(1-methylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 717905-57-2 CAPLUS

CN 2-Morpholinemethanamine, 4-acetyl-N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 717905-58-3 CAPLUS


CN 2-Morpholinemethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 717905-59-4 CAPLUS


CN 2-Morpholinemethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-4-(2,2-dimethyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

10/734039




RN 717905-60-7 CAPLUS

CN 4-Morpholinecarboxylic acid, 2-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 717905-61-8 CAPLUS

CN 2-Morpholinemethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-4-(methoxyacetyl)- (9CI) (CA INDEX NAME)



RN 717905-62-9 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[[[3-(ethylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 717905-63-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[3-(ethylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/734039



RN 717905-64-1 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(2S)-4-(methylsulfonyl)-2-morpholinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 717905-65-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(2-pyrimidinylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-66-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(pyrazinylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717905-67-4 CAPLUS

CN Methanesulfonamide, N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-4-fluorophenyl]-N-methyl- (9CI) (CA INDEX NAME)




10/734039




RN 717905-68-5 CAPLUS

CN 2-Morpholinemethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-4-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 717905-69-6 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[(3,3-dimethyl-2-oxobutyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717905-70-9 CAPLUS


CN 2H-Indol-2-one, 5-[[4-[(1,2-dimethylpropyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717905-71-0 CAPLUS


10/734039

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(2-methoxy-1-methylethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717905-72-1 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[[2-(1,1-dioxido-2-isothiazolidinyl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 717905-73-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[3-(methylamino)propyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-74-3 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(3-pyridinylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-75-4 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[6-(methylsulfonyl)-2-pyridinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/734039




RN 717905-76-5 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[[[3-(1,1-dioxido-2-isothiazolidinyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717905-77-6 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(1-methylethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-78-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(1R)-1-methylpropyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 717905-79-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(1S)-1-methylpropyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/734039



RN 717905-80-1 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[2-(methylamino)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-81-2 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(1S)-1-phenylethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 717905-82-3 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[2-[(methylsulfonyl)methyl]-4-thiazolyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-83-4 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-(propylamino)-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/734039




RN 717905-84-5 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(2-hydroxy-1-methylethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717905-85-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[1-(hydroxymethyl)propyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-86-7 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[5-(methylsulfonyl)-3-pyridinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-87-8 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(4-pyridinylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/734039




RN 717905-88-9 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[(1,3-dimethylbutyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717905-89-0 CAPLUS


CN Methanesulfonamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 717905-90-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(1S)-1-(hydroxymethyl)-2-methylpropyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 717905-91-4 CAPLUS

CN Methanesulfonamide, N-cyclohexyl-N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)


10/734039



RN 717905-93-6 CAPLUS


CN 3-Pyrrolidinemethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-1-(methylsulfonyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 717905-94-7 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(3-methyl-2-thienyl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717905-95-8 CAPLUS

CN 3-Pyrrolidinemethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-1-(methylsulfonyl)-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 717905-96-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(1S)-2-hydroxy-1-phenylethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/734039



RN 717905-97-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(1S)-2-hydroxy-1-methylethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 717905-98-1 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(1R)-1-(hydroxymethyl)propyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 717905-99-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[1-(4-pyrimidinyl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717906-02-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[(1H-imidazol-2-ylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717906-03-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[2-(2-piperidinyl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




10/734039

(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717906-04-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[methyl(2-methylpropyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717906-05-3 CAPLUS

CN Methanesulfonamide, N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 717906-06-4 CAPLUS


CN Methanesulfonamide, N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 717906-07-5 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[2-(methanesulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/734039




RN 717906-08-6 CAPLUS

CN Methanesulfonamide, N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]-N-(1-methylethyl)-(9CI) (CA INDEX NAME)




RN 717906-09-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[1-(2-pyridinyl)-3-piperidinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)



RN 717906-10-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[1-(2-pyrimidinyl)-3-piperidinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-(9CI) (CA INDEX NAME)




RN 717906-11-1 CAPLUS

CN 2-Piperidineethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-1-(methylsulfonyl)-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/734039



RN 717906-12-2 CAPLUS


CN 2-Piperidineethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-1-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 717906-13-3 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[3-(methylthio)propyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717906-14-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(1S)-1-(hydroxymethyl)-3-(methylthio)propyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 717906-15-5 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(1R)-2-hydroxy-1-methylethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/734039


Absolute stereochemistry.



RN 717906-16-6 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 717906-17-7 CAPLUS


CN Methanesulfonamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]aminopropyl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 717906-18-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(1S)-1-(hydroxymethyl)propyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 717906-19-9 CAPLUS


CN 2H-Indol-2-one, 5-[[4-[[[(3,5-dinitrophenyl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/734039




RN 717906-20-2 CAPLUS

CN Methanesulfonamide, N-[2-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 717906-21-3 CAPLUS

CN Methanesulfonamide, N-[2-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 717906-22-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(2-hydroxy-1-phenylethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717906-23-5 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

10/734039

INDEX NAME)


Absolute stereochemistry.



RN 717906-24-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(1S)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 717906-25-7 CAPLUS

CN 2-Piperidinemethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-1-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 717906-26-8 CAPLUS

CN 2-Pyrrolidinemethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-1-(methylsulfonyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/734039


RN 717906-27-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[methyl(2-pyridinylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717906-28-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[methyl[[3-(methanesulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717906-29-1 CAPLUS

CN Methanesulfonamide, N-[2-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 717906-30-4 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[methyl(3-pyridinylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717906-31-5 CAPLUS


CN 3-Piperidinemethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-N-methyl-1-(methanesulfonyl)- (9CI) (CA INDEX NAME)

10/734039




RN 717906-32-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[methyl(4-pyridinylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717906-34-8 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[[2,6-dimethoxyphenyl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 717906-35-9 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[[1,5-dimethyl-1H-pyrazol-3-yl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717906-36-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[2-(1H-imidazol-1-yl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717906-37-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(2-pyridinylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




10/734039

(trifluoromethyl)-2-pyrimidinyl]amino] - (9CI) (CA INDEX NAME)




RN 717906-38-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[5-(trifluoromethyl)-4-[[[2-(trifluoromethyl)phenyl]methyl]amino]-2-pyrimidinyl]amino] - (9CI) (CA INDEX NAME)




RN 717906-39-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[3-methyl-2-pyridinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino] - (9CI) (CA INDEX NAME)




RN 717906-40-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[3-(methylsulfonyl)phenyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino] - (9CI) (CA INDEX NAME)



RN 717906-41-7 CAPLUS


CN 2-Piperidineethanamine, 1-acetyl-N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl] - (9CI) (CA INDEX NAME)



RN 717906-42-8 CAPLUS


10/734039

CN 2-Piperidineethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 717906-43-9 CAPLUS

CN 2-Piperidineethanamine, 1-(cyclopropylcarbonyl)-N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 717906-44-0 CAPLUS

CN 2-Piperidineethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-1-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 717906-45-1 CAPLUS


CN 2-Piperidineethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-1-(1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 717906-46-2 CAPLUS


CN 2-Piperidineethanamine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-1-(methoxyacetyl)- (9CI) (CA INDEX NAME)

10/734039




RN 717906-47-3 CAPLUS

CN 2-Piperidineethanamine, 1-(cyclobutylcarbonyl)-N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 717906-48-4 CAPLUS

CN Acetamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 717906-49-5 CAPLUS


CN Propanamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 717906-50-8 CAPLUS


10/734039

CN Cyclopropanecarboxamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 717906-51-9 CAPLUS

CN Propanamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-N,2-dimethyl- (9CI) (CA INDEX NAME)




RN 717906-52-0 CAPLUS

CN Butanamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 717906-53-1 CAPLUS


CN Acetamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)



10/734039


RN 717906-54-2 CAPLUS

CN Cyclobutanecarboxamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 717906-55-3 CAPLUS

CN Propanamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-N,2,2-trimethyl- (9CI) (CA INDEX NAME)



RN 717906-57-5 CAPLUS


CN Butanamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-N,2-dimethyl- (9CI) (CA INDEX NAME)



RN 717906-58-6 CAPLUS


CN Benzamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-N-methyl- (9CI) (CA INDEX NAME)

10/734039




RN 717906-59-7 CAPLUS

CN 5-Isoxazolecarboxamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 717906-60-0 CAPLUS

CN 4-Morpholinecarboxamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 717906-61-1 CAPLUS


CN Ethanesulfonamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 717906-62-2 CAPLUS


CN 1-Propanesulfonamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-N-methyl- (9CI) (CA INDEX NAME)

10/734039




RN 717906-63-3 CAPLUS

CN Sulfamide, [3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]trimethyl- (9CI) (CA INDEX NAME)



RN 717906-64-4 CAPLUS


CN Acetamide, N-[3-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)



RN 717906-65-5 CAPLUS


CN Acetamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

10/734039




RN 717906-66-6 CAPLUS

CN Propanamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 717906-67-7 CAPLUS

CN Cyclopropanecarboxamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 717906-68-8 CAPLUS

CN Propanamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-N,2-dimethyl- (9CI) (CA INDEX NAME)




RN 717906-69-9 CAPLUS

CN Butanamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




10/734039




RN 717906-70-2 CAPLUS

CN Acetamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-2-methoxy-N-methyl- (9CI)  
(CA INDEX NAME)




RN 717906-71-3 CAPLUS

CN Cyclobutanecarboxamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 717906-72-4 CAPLUS


CN Propanamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-N,2,2-trimethyl- (9CI) (CA INDEX NAME)



RN 717906-73-5 CAPLUS


10/734039

CN Butanamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-N,2-dimethyl- (9CI) (CA INDEX NAME)




RN 717906-74-6 CAPLUS

CN Benzamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 717906-75-7 CAPLUS

CN 5-Isoxazolecarboxamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 717906-76-8 CAPLUS


CN 4-Morpholinecarboxamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 717906-77-9 CAPLUS


CN Ethanesulfonamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

10/734039




RN 717906-78-0 CAPLUS

CN 1-Propanesulfonamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 717906-79-1 CAPLUS


CN Sulfamide, [2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]trimethyl- (9CI) (CA INDEX NAME)



RN 717906-80-4 CAPLUS


CN Acetamide, N-[2-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)

10/734039




RN 717906-81-5 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(2-hydroxyethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717906-84-8 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[(1,4-dimethylpentyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717906-85-9 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[3-(1H-imidazol-1-yl)propyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717906-86-0 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(2-phenoxyethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/734039




RN 717906-87-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(1-cyclohexylethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 717906-88-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[1-(hydroxymethyl)-2,2-dimethylpropyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717906-89-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[1-(methoxymethyl)propyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717906-92-8 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[2-(2-oxo-1-imidazolidinyl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

O=C1NC(=O)CCN1CCNc2cc(F)(F)c3nc(NC4C(=O)NCC4)cnc32


CN Butanoic acid, 4-[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-9CI (CA INDEX NAME)




CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(3-hydroxy-2,2-dimethylpropyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




CN 2H-Indol-2-one, 5-[[[4-[[[(3,4-dihydro-1H-2-benzopyran-1-yl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/734039




RN 717907-01-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[2-[(2-hydroxyethyl)thio]ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717907-03-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[3-(3-pyridinyloxy)propyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717907-05-6 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[2-(6-methyl-2-pyridinyl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717907-07-8 CAPLUS


CN 2H-Indol-2-one, 5-[[4-[[[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/734039




RN 717907-09-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[1-methyl-1H-pyrazol-4-yl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717907-11-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[4,5,6,7-tetrahydro-2-benzothiazolyl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717907-13-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[1-phenyl-3-(1H-1,2,4-triazol-1-yl)propyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717907-15-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(2-methylpropyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)






10/734039

RN 717907-18-1 CAPLUS


CN 2H-Indol-2-one, 5-[[4-[[2-cyclohexyl-1-(hydroxymethyl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717907-20-5 CAPLUS


CN L-Alanine, N-[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 717907-24-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(3-hydroxypropyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717907-26-1 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[2-(4-methyl-1H-imidazol-2-yl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717907-30-7 CAPLUS


CN 2H-Indol-2-one, 5-[[4-[(dicyclopropylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/734039




RN 717907-32-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[2-(5-methyl-1H-1,2,4-triazol-3-yl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717907-34-1 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[[2-(ethylthio)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717907-36-3 CAPLUS


CN 2H-Indol-2-one, 5-[[4-[[2-(2-phenoxypropyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717907-38-5 CAPLUS


CN 2H-Indol-2-one, 5-[[4-[[[(1-ethyl-5-oxo-3-pyrrolidinyl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/734039




RN 717907-40-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[1-(2-methoxyethyl)-5-oxo-3-pyrrolidinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 717907-42-1 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[(diphenylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717907-44-3 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[2-(1-methyl-1H-pyrazol-4-yl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717907-45-4 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[4-methyl-1H-imidazol-2-yl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/734039




RN 717907-46-5 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[[5-cyclopropyl-1H-pyrazol-3-yl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 717907-47-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[2-(4-methyl-5-thiazolyl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717907-49-8 CAPLUS


CN 2H-Indol-2-one, 5-[[4-[[2-(1H-benzimidazol-2-yl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717907-50-1 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[5-methyl-1,3,4-oxadiazol-2-yl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/734039




RN 717907-51-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(5-phenyl-1H-1,2,4-triazol-3-yl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717907-52-3 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[(1H-indol-2-ylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717907-53-4 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717907-54-5 CAPLUS


CN 2H-Indol-2-one, 5-[[4-[(2-benzothiazolylmethyl)amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717907-55-6 CAPLUS


10/734039

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(3-methyl-5-isoxazolyl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717907-56-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(4-methyl-2-thiazolyl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717907-57-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[1-(4-methyl-2-thiazolyl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717907-58-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[5-(trifluoromethyl)-4-[[[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717907-59-0 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[1-(2-methyl-4-thiazolyl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717907-60-3 CAPLUS


10/734039

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[3-methylimidazo[2,1-b]thiazol-6-yl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717907-61-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[1-(5-methyl-1H-1,2,4-triazol-3-yl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 717907-62-5 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[1-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717907-63-6 CAPLUS


CN 2H-Indol-2-one, 5-[[4-[2-(3,5-dimethyl-1H-pyrazol-4-yl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717907-64-7 CAPLUS


CN 2H-Indol-2-one, 5-[[4-[2-(4,6-dimethyl-2-pyrimidinyl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)

10/734039




RN 717907-65-8 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[2-(5,6,7,8-tetrahydro-4-methyl-2-quinazolinyl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 717907-66-9 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[2-(4-thiazolyl)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 717907-67-0 CAPLUS

CN 2H-Indol-2-one, 5-[[4-(dimethylamino)-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 717907-68-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[1-methyl-2-(3-pyridinyloxy)ethyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




10/734039




RN 717907-69-2 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[4-(methanesulfonyl)-2-morpholinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI)  
(CA INDEX NAME)




RN 717907-70-5 CAPLUS

CN 2H-Indol-2-one, 5-[[4-[(bicyclo[2.2.1]hept-5-en-2-yl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 717907-71-6 CAPLUS


CN Methanesulfonamide, N-[2-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-6-methylphenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 717907-73-8 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-[[[(1-hydroxycyclopentyl)methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/734039




RN 717907-74-9 CAPLUS

CN 2-Piperidinemethanol,  $\alpha$ -[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 717907-75-0 CAPLUS

CN Methanesulfonamide, N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:515487 CAPLUS

DN 141:71555

TI Preparation of nitrogen-containing heterocyclic compounds as CXCR4 regulators

IN Habashita, Hiromu; Kokubo, Masaya; Shibayama, Shiro; Tada, Hideaki; Tanihiro, Tatsuya

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 641 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052862	A1	20040624	WO 2003-JP15718	20031209
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,			

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1571146 A1 20050907 EP 2003-778753 20031209

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRAI JP 2002-357446 A 20021210

JP 2003-162706 A 20030606

WO 2003-JP15718 W 20031209

OS MARPAT 141:71555


IT 711001-01-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nitrogen-containing heterocyclic compds. as CXCR4 antagonists for preparation and/treatment of diseases)

RN 711001-01-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(2,3-dihydro-1H-inden-1-yl)-N4-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:467870 CAPLUS

DN 141:38625

TI Preparation of Chk-, pdk- and akt-inhibitory pyrimidines

IN Bryant, Judi; Kochanny, Monica; Yuan, Shendong; Khim, Seock-Kuy; Buckman, Brad; Arnaiz, Damian; Boemer, Ulf; Briem, Hans; Esperling, Peter; Huwe, Peter; Kuhnke, Joachim; Schaefer, Martina; Wortmann, Lars; Kosemund, Dirk; Eckle, Emil; Feldman, Richard; Phillips, Gary

PA Schering Aktiengesellschaft, Germany

SO PCT Int. Appl., 293 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004048343	A1	20040610	WO 2003-EP13443	20031128
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2502970	AA	20040610	CA 2003-2502970	20031128

10/734039


US 2004186118 A1 20040923 US 2003-722591 20031128  
EP 1565446 A1 20050824 EP 2003-780086 20031128  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
BR 2003016680 A 20051018 BR 2003-16680 20031128  
PRAI EP 2002-26607 A 20021128  
WO 2003-EP13443 W 20031128  
OS MARPAT 141:38625  
IT 702674-48-4P 702674-67-7P 702674-72-4P  
702675-83-0P 702675-90-9P 702675-91-0P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)  
(preparation of Chk-, pdk- and akt-inhibitory pyrimidines)  
RN 702674-48-4 CAPLUS  
CN 2H-Benzimidazol-2-one, 5-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-  
pyrimidinyl]amino]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 702674-67-7 CAPLUS  
CN 1H-Isoindole-1,3(2H)-dione, 5-[[5-bromo-4-[[2-(1H-imidazol-4-  
yl)ethyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 702674-72-4 CAPLUS  
CN 2,4-Pyrimidinediamine, N2-1,3-benzodioxol-5-yl-5-bromo-N4-[2-(1H-imidazol-  
4-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 702675-83-0 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(1H-imidazol-4-yl)ethyl]-N2-(2-methyl-  
6-quinolinyl)- (9CI) (CA INDEX NAME)

10/734039




RN 702675-90-9 CAPLUS

CN 1-Naphthaleneacetic acid, 4-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 702675-91-0 CAPLUS

CN 1H-Indole-2-carboxylic acid, 5-[[5-bromo-4-[[2-(1H-imidazol-4-yl)ethyl]amino]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:453191 CAPLUS

DN 141:23546

TI Preparation of 2,4-bis(phenylamino)pyrimidine derivatives for treating hyperproliferative disorders

IN Wood, Jill E.; Bierer, Donald; Bear, Brian; Brennan, Catherine; Chandler, Brent; Chen, Gang; Chen, Yuanwei; Dixon, Julie; Fu, Wenlang; Guernon, Leatte; Liu, Donglei; McClure, Andrea; Miranda, Karl; Nagarathnam, Dhanapalan; Sibley, Robert; Turner, Michael; Verma, Sharad; Wang, Chunguang; Yi, Lin; Zhao, Jin; Zhu, Qingming

PA Bayer Pharmaceuticals Corporation, USA

SO PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.


KIND

DATE


APPLICATION NO.

DATE

PI WO 2004046118 A2 20040603 WO 2003-US14294 20030506  
 WO 2004046118 A3 20040812  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 PRAI US 2002-378329P P 20020506  
 OS MARPAT 141:23546  
 IT **698995-85-6P**, 4-[2-[[5-Bromo-2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-4-pyrimidinyl]amino]ethyl]benzenesulfonamide **698995-91-4P**, 4-[2-[[5-Bromo-2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-4-pyrimidinyl]amino]ethyl]benzenesulfonamide hydrochloride **698996-96-2P**, N-(1H-Indol-5-yl)-N-[5-methyl-4-[(2-methylbenzyl)amino]-2-pyrimidinyl]amine **698996-97-3P**, N-[5-Bromo-4-[(2,5-dichlorobenzyl)amino]-2-pyrimidinyl]-N-(1H-indol-5-yl)amine **698997-02-3P**, N-(2-Methylbenzyl)-N-[5-methyl-2-[(1-methyl-1H-indol-5-yl)amino]-4-pyrimidinyl]amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 2,4-bis(phenylamino)pyrimidine derivs. for treating hyperproliferative disorders)  
 RN 698995-85-6 CAPLUS  
 CN Benzenesulfonamide, 4-[2-[[5-bromo-2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 698995-91-4 CAPLUS  
 CN Benzenesulfonamide, 4-[2-[[5-bromo-2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



10/734039


RN 698996-96-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-1H-indol-5-yl-5-methyl-N4-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 698996-97-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(2,5-dichlorophenyl)methyl]-N2-1H-indol-5-yl- (9CI) (CA INDEX NAME)



RN 698997-02-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-methyl-N2-(1-methyl-1H-indol-5-yl)-N4-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 25 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:236703 CAPLUS

DN 140:423636

TI Solid-Phase Synthesis of 2,4-Diaminopyrimidines via Lewis Acid-Mediated Aromatic Nucleophilic Substitution

AU Arvanitis, Elena A.; Chadha, Naresh; Pottorf, Richard S.; Player, Mark R.

CS 3-Dimensional Pharmaceuticals Inc., Cranbury, NJ, 08512, USA

SO Journal of Combinatorial Chemistry (2004), 6(3), 414-419

CODEN: JCCHFF; ISSN: 1520-4766

PB American Chemical Society

DT Journal

LA English

OS CASREACT 140:423636

IT 691402-37-6P 691402-55-8P 691402-73-0P

691402-91-2P 691403-09-5P 691403-28-8P

691403-50-6P 691403-77-7P 691404-04-3P

691404-31-6P 691404-54-3P 691404-80-5P

691405-02-4P 691405-20-6P 691405-39-7P

691405-58-0P 691405-76-2P 691405-94-4P

10/734039

RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)

(solid-phase combinatorial synthesis of 2,4-diaminopyrimidines via Lewis acid-mediated aromatic nucleophilic substitution)


RN 691402-37-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N4-(phenylmethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-36-5


CMF C19 H18 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691402-55-8 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N4-[(tetrahydro-2-furanyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-54-7

CMF C17 H20 N4 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2




10/734039



RN 691402-73-0 CAPLUS  
CN 2,4-Pyrimidinediamine, N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N4-[(4-methylphenyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691402-72-9  
CMF C20 H20 N4 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 691402-91-2 CAPLUS  
CN 2,4-Pyrimidinediamine, N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N4-[3-(1-methylethoxy)propyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691402-90-1  
CMF C18 H24 N4 O3



CM 2

CRN 76-05-1  
CMF C2 H F3 O2

10/734039




RN 691403-09-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-(2,4-dichlorophenyl)ethyl]-N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-08-4


CMF C20 H18 Cl2 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691403-28-8 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N4-[2-(3,4-dimethoxyphenyl)ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-27-7


CMF C22 H24 N4 O4



CM 2

10/734039


CRN 76-05-1  
CMF C2 H F3 O2



RN 691403-50-6 CAPLUS  
CN 2,4-Pyrimidinediamine, N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N4-[(2-methoxyphenyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691403-49-3  
CMF C20 H20 N4 O3



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 691403-77-7 CAPLUS  
CN 2,4-Pyrimidinediamine, N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N4-[(4-fluorophenyl)methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691403-76-6  
CMF C19 H17 F N4 O2



CM 2

10/734039


CRN 76-05-1  
CMF C2 H F3 O2



RN 691404-04-3 CAPLUS  
CN 2,4-Pyrimidinediamine, N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-N4-propyl-,  
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 691404-03-2  
CMF C15 H18 N4 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 691404-31-6 CAPLUS  
CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-  
[(phenylmethyl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-30-5  
CMF C20 H17 N5 O2




10/734039

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-54-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-  
[[tetrahydro-2-furanyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA  
INDEX NAME)

CM 1

CRN 691404-53-2


CMF C18 H19 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691404-80-5 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-  
[[4-methylphenyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX  
NAME)

CM 1

CRN 691404-79-2

CMF C21 H19 N5 O2


10/734039



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-02-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-[[3-(1-methylethoxy)propyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-01-3


CMF C19 H23 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691405-20-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

10/734039

CM 1

CRN 691405-19-3


CMF C21 H17 Cl2 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-39-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-38-6


CMF C23 H23 N5 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691405-58-0 CAPLUS


10/734039

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-[[ (2-methoxyphenyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-57-9


CMF C21 H19 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-76-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-[[ (4-fluorophenyl)methyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-75-1

CMF C20 H16 F N5 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2



10/734039




RN 691405-94-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-(propylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-93-3


CMF C16 H17 N5 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:142963 CAPLUS

DN 140:199334

TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor  
modulators for treatment of autoimmune diseases

IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Clough, Jeffrey; Keim,  
Holger; Sylvain, Catherine; Li, Hui; Bhamidipati, Somasekhar

PA Rigel Pharmaceuticals, USA

SO PCT Int. Appl., 811 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2004014382	A1	20040219	WO 2003-US24087	20030729
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,			

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2492325 AA 20040219 CA 2003-2492325 20030729  
 EP 1534286 A1 20050601 EP 2003-784871 20030729

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003013059 A 20050705 BR 2003-13059 20030729  
 US 2005038243 A1 20050217 US 2004-858343 20040601  
 US 2005209230 A1 20050922 US 2004-911684 20040803  
 SE 2005000203 A 20050329 SE 2005-203 20050127

PRAI US 2002-399673P P 20020729  
 US 2003-443949P P 20030131  
 US 2003-452339P P 20030306  
 US 2003-631029 A 20030729  
 US 2002-353267P P 20020201  
 US 2002-353333P P 20020201  
 US 2002-434277P P 20021217  
 US 2003-355543 A1 20030131  
 WO 2003-US24087 W 20030729


OS MARPAT 140:199334  
 IT 575476-84-5P 575477-13-3P 575477-16-6P  
 575477-28-0P 575482-10-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases)

RN 575476-84-5 CAPLUS  
 CN Benzenemethanol,  $\alpha$ -[(1S)-1-[[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-4-pyrimidinyl]amino]ethyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 575477-13-3 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[(5-chlorobenzo[b]thien-3-yl)methyl]-N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-fluoro- (9CI) (CA INDEX NAME)



RN 575477-16-6 CAPLUS



10/734039

CN 2,4-Pyrimidinediamine, N4-[2-[[[2-chloro-6-fluorophenyl)methyl]thio]ethyl]-  
N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-fluoro- (9CI) (CA INDEX NAME)



RN 575477-28-0 CAPLUS


CN Benzoic acid, [[[5-cyano-2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 575482-10-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-[[[1S]-2-ethoxy-2-oxo-1-phenylethyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

10/734039

AN 2004:20665 CAPLUS  
DN 140:94057  
TI Preparation of 2,4-diaminopyrimidine-5-carboxamide derivatives as  
inhibitors of signal transducer and activator of transcription (STAT6)  
IN Nagashima, Shinya; Nagata, Hiroshi; Iwata, Masahiro; Yokota, Masaki;  
Moritomo, Hiroyuki; Nakai, Eiichi; Kuromitsu, Sadao; Ohga, Keiko;  
Takeuchi, Makoto  
PA Yamanouchi Pharmaceutical Co., Ltd., Japan  
SO PCT Int. Appl., 102 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002964	A1	20040108	WO 2003-JP8129	20030626
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2490888	AA	20040108	CA 2003-2490888	20030626
	EP 1518855	A1	20050330	EP 2003-761820	20030626
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	JP 2002-190959	A	20020628		
	WO 2003-JP8129	W	20030626		

OS MARPAT 140:94057


IT 643090-54-4P 643090-58-8P 643090-59-9P  
643090-61-3P 643090-63-5P 643090-64-6P  
643090-65-7P 643090-66-8P 643090-67-9P  
643090-68-0P 643090-69-1P 643090-70-4P  
643090-71-5P 643090-72-6P 643090-74-8P  
643090-76-0P 643090-77-1P 643090-78-2P  
643090-80-6P 643090-81-7P 643090-82-8P  
643090-83-9P 643090-84-0P 643090-85-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diaminopyrimidinecarboxamide derivs. as inhibitors of signal transducer and activator of transcription (STAT6), Th2 cell differentiation inhibitors, and preventives and/therapeutics for respiratory diseases)

RN 643090-54-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-58-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2,3-dihydro-1-methyl-1H-indol-5-yl)amino]-4-


10/734039

[[ (2-fluorophenyl)methyl]amino] - (9CI) (CA INDEX NAME)




RN 643090-59-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[(1,2,3,4-tetrahydro-1-methyl-6-quinolinyl)amino] - (9CI) (CA INDEX NAME)




RN 643090-61-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(phenylmethyl)amino]-2-[(1,2,3,4-tetrahydro-2-methyl-7-isoquinolinyl)amino] - (9CI) (CA INDEX NAME)



RN 643090-63-5 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[(2,3-dihydro-1-methyl-1H-indol-5-yl)amino]-4-[(phenylmethyl)amino] - (9CI) (CA INDEX NAME)



RN 643090-64-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[(2,3-dihydro-1-methyl-1H-indol-6-yl)amino]-4-[(phenylmethyl)amino] - (9CI) (CA INDEX NAME)

10/734039




RN 643090-65-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[(1,2,3,4-tetrahydro-1-methyl-7-quinolinyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-66-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(1-methyl-1H-indol-5-yl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 643090-67-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[(1-acetyl-2,3-dihydro-1H-indol-5-yl)amino]-4-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 643090-68-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-(6-quinolinylamino)- (9CI) (CA INDEX NAME)


10/734039




RN 643090-69-1 CAPLUS  
CN 5-Pyrimidinecarboxamide, 2-((1H-indol-5-yl)amino)-4-((phenylmethyl)amino)-  
(9CI) (CA INDEX NAME)



RN 643090-70-4 CAPLUS  
CN 5-Pyrimidinecarboxamide, 2-((1H-indazol-5-yl)amino)-4-((phenylmethyl)amino)-  
(9CI) (CA INDEX NAME)




RN 643090-71-5 CAPLUS  
CN 5-Pyrimidinecarboxamide, 2-((1H-indazol-6-yl)amino)-4-((phenylmethyl)amino)-  
(9CI) (CA INDEX NAME)




RN 643090-72-6 CAPLUS  
CN 5-Pyrimidinecarboxamide, 2-((2,3-dihydro-1,4-benzodioxin-6-yl)amino)-4-  
((phenylmethyl)amino)- (9CI) (CA INDEX NAME)

10/734039



RN 643090-74-8 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[(1,2,3,4-tetrahydro-2-methyl-1-oxo-6-isoquinolinyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 643090-76-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[(1,2,3,4-tetrahydro-2-methyl-6-isoquinolinyl)amino]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 643090-77-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[(phenylmethyl)amino]-2-[(1,2,3,4-tetrahydro-2-methyl-1-oxo-7-isoquinolinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




10/734039



● HCl

RN 643090-78-2 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)amino]-4-[[[(2,3,6-trifluorophenyl)methyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 643090-80-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[(2-methyl-1H-indol-5-yl)amino]-4-[[[(2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 643090-81-7 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-(6-benzothiazolylamino)-4-[[[(2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

10/734039




RN 643090-82-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2,3-dihydro-1-oxo-1H-inden-5-yl)amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)




RN 643090-83-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2-oxo-2H-1-benzopyran-6-yl)amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 643090-84-0 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[[2-(trifluoromethyl)-1H-benzimidazol-5-yl]amino]-4-[[2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 643090-85-1 CAPLUS

10/734039

CN 5-Pyrimidinecarboxamide, 2-[(1-methyl-1H-indol-5-yl)amino]-4-[[[(2,3,6-trifluorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:610204 CAPLUS

DN 139:164801

TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction

IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Molineaux, Susan; Holland, Sacha J.; Clough, Jeffrey; Keim, Holger; Bhamidipati, Somasekhar; Sylvain, Catherine; Li, Weigun; Rossi, Alexander B.

PA Rigel Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 648 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003063794	A2	20030807	WO 2003-US3022	20030131
	WO 2003063794	A3	20031204		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2474277	AA	20030807	CA 2003-2474277	20030131
	US 2004029902	A1	20040212	US 2003-355543	20030131
	EP 1471915	A2	20041103	EP 2003-707654	20030131
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005516046	T2	20050602	JP 2003-563490	20030131
	US 2005038243	A1	20050217	US 2004-858343	20040601
	US 2005209230	A1	20050922	US 2004-911684	20040803
	NO 2004003632	A	20041026	NO 2004-3632	20040831
PRAI	US 2002-353267P	P	20020201		
	US 2002-353333P	P	20020201		
	US 2002-399673P	P	20020729		
	US 2002-434277P	P	20021217		
	US 2003-355543	A1	20030131		
	WO 2003-US3022	W	20030131		

10/734039

OS MARPAT 139:164801

IT 575476-84-5P 575477-13-3P 575477-16-6P

575477-28-0P 575482-10-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction)

RN 575476-84-5 CAPLUS


CN Benzenemethanol,  $\alpha$ -[(1S)-1-[[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-5-fluoro-4-pyrimidinyl]amino]ethyl]-, ( $\alpha$ R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 575477-13-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(5-chlorobenzo[b]thien-3-yl)methyl]-N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-fluoro- (9CI) (CA INDEX NAME)



RN 575477-16-6 CAPLUS



CN 2,4-Pyrimidinediamine, N4-[2-[[[(2-chloro-6-fluorophenyl)methyl]thio]ethyl]-N2-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-fluoro- (9CI) (CA INDEX NAME)



RN 575477-28-0 CAPLUS

CN Benzoic acid, [[[5-cyano-2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-pyrimidinyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)


10/734039



RN 575482-10-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-4-  
[[ (1S) -2-ethoxy-2-oxo-1-phenylethyl]amino]-, ethyl ester (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.



L4 ANSWER 29 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:319721 CAPLUS

DN 138:321292

TI Preparation of 2,4,5-trisubstituted pyrimidines as cyclin dependent kinase inhibitors

IN Dahmann, Georg; Himmelsbach, Frank; Wittneben, Helmut; Pautsch, Alexander; Prokopowicz, Anthony S.; Krist, Bernd; Schnapp, Gisela; Steegmaier, Martin; Lenter, Martin; Schoop, Andreas; Steurer, Steffen; Spevak, Walter

PA Boehringer Ingelheim Pharma K.-G., Germany; Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International G.m.b.H.

SO PCT Int. Appl., 278 pp.  
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003032997	A1	20030424	WO 2002-EP11453	20021014
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


CA 2463989	AA 20030424	CA 2002-2463989	20021014
EP 1438053	A1 20040721	EP 2002-774710	20021014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005509624	T2 20050414	JP 2003-535800	20021014
US 2003171359	A1 20030911	US 2002-271763	20021016
PRAI US 2001-330145P	P 20011017		
WO 2002-EP11453	W 20021014		
OS MARPAT 138:321292			
IT 514830-62-7P 514837-20-8P 514837-22-0P			
514837-24-2P 514837-47-9P, 3-[(2-((1-Methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-yl)amino]propylamine			
514837-76-4P, [3-[(2-((1-Methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-yl)amino]propyl]carbamic acid benzyl ester			
514837-88-8P, 2-(1-Naphthylamino)-4-[N-(trans-4-hydroxycyclohexyl)-N-methylamino]-5-nitropyrimidine 514838-09-6P,			
2-(1,3-Dihydro-2-oxoindol-6-ylamino)-4-[N-(trans-4-hydroxycyclohexyl)-N-methylamino]-5-nitropyrimidine 514838-16-5P,			
2-(6-Indazolylamino)-4-[N-(trans-4-hydroxycyclohexyl)-N-methylamino]-5-nitropyrimidine 514838-25-6P, 2-(5-Carboxy-2-naphthylamino)-4-(2-acetylaminooethylamino)-5-nitropyrimidine 514838-26-7P,			
2-(5-Carboxy-2-naphthylamino)-4-(ethoxycarbonylmethylamino)-5-nitropyrimidine 514838-32-5P, 1-[3-[2-((1H-Benzotriazol-5-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]propyl]pyrrolidin-2-one			
514838-34-7P, 1-[3-[2-((1H-Benzimidazol-5-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]propyl]pyrrolidin-2-one			
514838-35-8P, 1-[3-[2-((1H-Indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]propyl]pyrrolidin-2-one			
514838-39-2P, N-[2-[5-Chloro-2-((1H-indazol-6-yl)amino)pyrimidin-4-ylamino]ethyl]acetamide 514838-42-7P, N-[2-[2-((1H-Benzotriazol-5-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]ethyl]acetamide			
514838-44-9P, N-[2-[2-((1H-Benzimidazol-5-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]ethyl]acetamide 514838-45-0P,			
N-[2-[2-((1H-Indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]ethyl]acetamide 514838-47-2P, N-[2-[2-((1H-Indazol-5-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]ethyl]acetamide			
514838-52-9P, 1-[3-[5-Chloro-2-((1H-indazol-6-yl)amino)pyrimidin-4-yl)amino]propyl]pyrrolidin-2-one 514838-89-2P,			
N-[2-[(2-((1H-Indazol-6-yl)amino)-5-methylpyrimidin-4-yl)amino]ethyl]acetamide 514838-90-5P, 1-[3-[(2-((1H-Indazol-6-yl)amino)-5-methylpyrimidin-4-yl)amino]propyl]pyrrolidin-2-one			
514838-94-9P, N-[2-[(5-Bromo-2-((1H-indazol-6-yl)amino)pyrimidin-4-yl)amino]ethyl]acetamide 514839-40-8P, 1-[3-[(5-Bromo-2-((1H-indazol-6-yl)amino)pyrimidin-4-yl)amino]propyl]pyrrolidin-2-one			
514840-06-3P 514840-07-4P 514840-09-6P			
514840-11-0P 514840-13-2P 514840-14-3P			
514840-16-5P 514840-39-2P, N-[3-[(2-((1-Methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-yl)amino]propyl]isobutaneamide 514840-47-2P,			
N-[3-[(2-((1-Methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-yl)amino]propyl]propionamide 514840-48-3P, N-[3-[2-((1-Methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]propyl]methansulfonamide 514840-55-2P,			
4-Fluoro-N-[3-[2-((1-methyl-1H-indazol-6-yl)amino)-5-			

trifluoromethylpyrimidin-4-ylamino]propyl]benzenesulfonamide  
**514840-56-3P**, 2-Methoxy-N-[3-[2-((1-methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]propyl]acetamide **514840-59-6P**,  
 3-Methyl-N-[3-[2-((1-methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]propyl]butaneamide **514840-61-0P**,  
 2-Fluoro-N-[3-[2-((1-methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]propyl]benzenesulfonamide  
**514840-69-8P**, N-[3-[2-((1-Methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]propyl]-2-phenylacetamide  
**514840-71-2P**, Methyl [3-[2-((1-methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]propyl]carbamate **514840-74-5P**,  
 Isobutyl [3-[2-((1-methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]propyl]carbamate **514840-76-7P**,  
 2-Chlorobenzyl [3-[2-((1-methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]propyl]carbamate **514840-85-8P**,  
 N-[3-[2-((1-Methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]propyl]benzenesulfonamide **514840-87-0P**,  
 N,N-Diethyl-N'-[3-[2-((1-methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]propyl]urea **514840-93-8P**,  
 N,N-Dimethyl-N'-[3-[2-((1-methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]propyl]urea **514840-95-0P**,  
 N-Isopropyl-N'-[3-[2-((1-methyl-1H-indazol-6-yl)amino)-5-trifluoromethylpyrimidin-4-ylamino]propyl]urea  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of trisubstituted pyrimidines as cyclin dependent kinase inhibitors)


RN 514830-62-7 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[2-(2-naphthalenylamino)-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 514837-20-8 CAPLUS


CN Acetamide, N-[2-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 514837-22-0 CAPLUS


CN Acetamide, N-[2-[[2-[(1-methyl-1H-indazol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

10/734039




RN 514837-24-2 CAPLUS

CN Acetamide, N-[2-[[2-[(2-methyl-2H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 514837-47-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(3-aminopropyl)-N2-(1-methyl-1H-indazol-6-yl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 514837-76-4 CAPLUS

CN Carbamic acid, [3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 514837-88-8 CAPLUS

CN Cyclohexanol, 4-[methyl[2-(1-naphthalenylamino)-5-nitro-4-pyrimidinyl]amino]-, trans- (9CI) (CA INDEX NAME)



10/734039


Relative stereochemistry.



RN 514838-09-6 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-[[4-[(trans-4-hydroxycyclohexyl)methylamino]-5-nitro-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 514838-16-5 CAPLUS


CN Cyclohexanol, 4-[[2-(1H-indazol-6-ylamino)-5-nitro-4-pyrimidinyl]methylamino]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 514838-25-6 CAPLUS


CN 1-Naphthalenecarboxylic acid, 6-[[4-[[2-(acetylamino)ethyl]amino]-5-nitro-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 514838-26-7 CAPLUS


CN 1-Naphthalenecarboxylic acid, 6-[[4-[(2-ethoxy-2-oxoethyl)amino]-5-nitro-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

10/734039




RN 514838-32-5 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[2-(1H-benzotriazol-5-ylamino)-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 514838-34-7 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[2-(1H-benzimidazol-5-ylamino)-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 514838-35-8 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[2-(1H-indazol-6-ylamino)-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 514838-39-2 CAPLUS

CN Acetamide, N-[2-[[5-chloro-2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

10/734039


AcNH-CH<sub>2</sub>-CH<sub>2</sub>-NH



RN 514838-42-7 CAPLUS

CN Acetamide, N-[2-[[2-(1H-benzotriazol-5-ylamino)-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


AcNH-CH<sub>2</sub>-CH<sub>2</sub>-NH



RN 514838-44-9 CAPLUS

CN Acetamide, N-[2-[[2-(1H-benzimidazol-5-ylamino)-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


AcNH-CH<sub>2</sub>-CH<sub>2</sub>-NH



RN 514838-45-0 CAPLUS

CN Acetamide, N-[2-[[2-(1H-indazol-6-ylamino)-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)


AcNH-CH<sub>2</sub>-CH<sub>2</sub>-NH



RN 514838-47-2 CAPLUS


CN Acetamide, N-[2-[[2-(1H-indazol-5-ylamino)-5-(trifluoromethyl)-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

10/734039




RN 514838-52-9 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[5-chloro-2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 514838-89-2 CAPLUS

CN Acetamide, N-[2-[[2-(1H-indazol-6-ylamino)-5-methyl-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 514838-90-5 CAPLUS


CN 2-Pyrrolidinone, 1-[3-[[2-(1H-indazol-6-ylamino)-5-methyl-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 514838-94-9 CAPLUS


CN Acetamide, N-[2-[[5-bromo-2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

10/734039




RN 514839-40-8 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[5-bromo-2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 514840-06-3 CAPLUS

CN Acetamide, N-[2-[[5-methyl-2-[[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroethyl)-1H-3-benzazepin-7-yl]amino]-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 514840-07-4 CAPLUS


CN Acetamide, N-[2-[[5-chloro-2-[[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroethyl)-1H-3-benzazepin-7-yl]amino]-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 514840-09-6 CAPLUS


CN 2-Pyrrolidinone, 1-[3-[[2-[[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroethyl)-1H-3-benzazepin-7-yl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)

10/734039




RN 514840-11-0 CAPLUS

CN Acetamide, N-[2-[[5-bromo-2-[[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroethyl)-1H-3-benzazepin-7-yl]amino]-4-pyrimidinyl]amino]ethyl]-(9CI) (CA INDEX NAME)




RN 514840-13-2 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[[5-methyl-2-[[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroethyl)-1H-3-benzazepin-7-yl]amino]-4-pyrimidinyl]amino]propyl]-(9CI) (CA INDEX NAME)



RN 514840-14-3 CAPLUS


CN 2-Pyrrolidinone, 1-[3-[[5-chloro-2-[[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroethyl)-1H-3-benzazepin-7-yl]amino]-4-pyrimidinyl]amino]propyl]-(9CI) (CA INDEX NAME)



RN 514840-16-5 CAPLUS


CN 2-Pyrrolidinone, 1-[3-[[5-bromo-2-[[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroethyl)-1H-3-benzazepin-7-yl]amino]-4-pyrimidinyl]amino]propyl]-(9CI) (CA INDEX NAME)

10/734039




RN 514840-39-2 CAPLUS

CN Propanamide, 2-methyl-N-[3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 514840-47-2 CAPLUS

CN Propanamide, N-[3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 514840-48-3 CAPLUS


CN Methanesulfonamide, N-[3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 514840-55-2 CAPLUS


CN Benzenesulfonamide, 4-fluoro-N-[3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)

10/734039




RN 514840-56-3 CAPLUS

CN Acetamide, 2-methoxy-N-[3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 514840-59-6 CAPLUS

CN Butanamide, 3-methyl-N-[3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 514840-61-0 CAPLUS

CN Benzenesulfonamide, 2-fluoro-N-[3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 514840-69-8 CAPLUS

CN Benzeneacetamide, N-[3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)




10/734039




RN 514840-71-2 CAPLUS

CN Carbamic acid, [3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 514840-74-5 CAPLUS

CN Carbamic acid, [3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)



RN 514840-76-7 CAPLUS


CN Carbamic acid, [3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]-, (2-chlorophenyl)methyl ester (9CI) (CA INDEX NAME)



10/734039


RN 514840-85-8 CAPLUS

CN Benzenesulfonamide, N-[3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 514840-87-0 CAPLUS

CN Urea, N,N-diethyl-N'-[3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 514840-93-8 CAPLUS

CN Urea, N,N-dimethyl-N'-[3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 514840-95-0 CAPLUS

CN Urea, N-(1-methylethyl)-N'-[3-[[2-[(1-methyl-1H-indazol-6-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2003:319718 CAPLUS  
DN 138:338160  
TI Preparation of diaminopyrimidines as inhibitors of  $\beta$  amyloid  
formation or its release  
IN Himmelsbach, Frank; Fuchs, Klaus; Briem, Hans; Fechteler, Katja; Kostka,  
Markus; Dorner-Ciossek, Cornelia; Bornemann, Klaus; Klinder, Klaus  
PA Boehringer Ingelheim Pharma K.-G., Germany  
SO PCT Int. Appl., 88 pp.  
CODEN: PIXXD2  
DT Patent  
LA German  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003032994	A2	20030424	WO 2002-EP11345	20021010
	WO 2003032994	A3	20030612		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				
	UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1453516	A2	20040908	EP 2002-772368	20021010
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	US 2003134838	A1	20030717	US 2002-272160	20021016
	US 2005090486	A1	20050428	US 2004-7923	20041209
PRAI	US 2001-330128P	P	20011017		
	WO 2002-EP11345	W	20021010		
	US 2002-272160	B1	20021016		


OS MARPAT 138:338160

IT 515825-03-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of diaminopyrimidines useful for inhibiting  $\beta$  amyloid  
formation or its release)

RN 515825-03-3 CAPLUS

CN 1H-3-Benzazepin-7-amine, 2,3,4,5-tetrahydro-N-[4-(methylamino)-5-nitro-2-  
pyrimidinyl]-3-(trifluoroacetyl)- (9CI) (CA INDEX NAME)



IT 515825-13-5P 515825-22-6P 515825-55-5P


515826-07-0P 515826-36-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diaminopyrimidines useful for inhibiting  $\beta$  amyloid formation or its release)


RN 515825-13-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(2,3-dihydro-1H-inden-5-yl)-N4-methyl-5-nitro- (9CI) (CA INDEX NAME)




RN 515825-22-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-methyl-N2-2-naphthalenyl-5-nitro- (9CI) (CA INDEX NAME)



RN 515825-55-5 CAPLUS


CN 2,4,5-Pyrimidinetriamine, N2-(2,3-dihydro-1H-inden-5-yl)-N4-methyl- (9CI) (CA INDEX NAME)




RN 515826-07-0 CAPLUS

CN 4-Morpholinecarboxamide, N-[2-[(2,3-dihydro-1H-inden-5-yl)amino]-4-(methylamino)-5-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/734039



RN 515826-36-5 CAPLUS  
CN 2,4-Pyrimidinediamine, N4-methyl-5-nitro-N2-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2003:300895 CAPLUS  
DN 138:321288  
TI Preparation of 2- and 4-aminopyrimidines N-substituted by a bicyclic ring-  
for use as kinase inhibitors in the treatment of cancer  
IN Nagarathnam, Dhanapalan; Wang, Chunguang; Chen, Yuanwei; Yi, Lin; Chen,  
Jianqing; Weber, Olaf; Boyer, Stephen; Clark, Roger B.; Phillips, Barton;  
Meahl, Jennifer; Ladouceur, Gaetan; Bi, Cheng; Burke, Michael J.; Cook,  
James; Verma, Sharad K.; Fan, Jianmei  
PA Bayer Corporation, USA  
SO PCT Int. Appl., 118 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003030909	A1	20030417	WO 2002-US30616	20020925
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2001-324276P	P	20010925		
	US 2002-352509P	P	20020131		
OS	MARPAT 138:321288				
IT	511244-80-7P 511246-41-6P 511246-43-8P 511246-45-0P 511246-47-2P 511246-50-7P 511246-60-9P 511246-63-2P 511246-65-4P 511246-68-7P 511246-86-9P 511246-97-2P 511246-99-4P 511247-01-1P 511247-03-3P 511247-11-3P 511247-18-0P 511247-19-1P 511247-20-4P 511247-21-5P 511247-22-6P 511247-23-7P 511247-37-3P 511247-54-4P				


511247-55-5P 511247-56-6P 511247-57-7P  
 511247-58-8P 511247-59-9P 511247-63-5P  
 511247-65-7P 511247-66-8P 511247-67-9P  
 511247-68-0P 511247-70-4P 511247-71-5P  
 511247-72-6P 511247-74-8P 511247-86-2P  
 511247-89-5P 511247-91-9P 511247-92-0P  
 511247-93-1P 511247-94-2P 511247-95-3P  
 511247-96-4P 511247-97-5P 511247-99-7P  
 511248-00-3P 511248-02-5P 511248-04-7P  
 511248-05-8P 511248-08-1P 511248-09-2P  
 511248-10-5P 511248-12-7P 511248-13-8P  
 511248-14-9P 511248-15-0P 511248-16-1P  
 511248-17-2P 511248-18-3P 511248-19-4P  
 511248-20-7P 511248-21-8P 511248-22-9P  
 511248-24-1P 511248-25-2P 511248-26-3P  
 511248-29-6P 511248-30-9P 511248-31-0P  
 511248-32-1P 511248-33-2P 511248-38-7P  
 511248-39-8P 511248-40-1P 511248-49-0P  
 511248-52-5P 511248-53-6P 511248-54-7P  
 511248-55-8P 511248-57-0P 511248-59-2P  
 511248-81-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2- and 4-aminopyrimidines as kinase inhibitors in the treatment of cancer)

RN 511244-80-7 CAPLUS

CN Benzenesulfonamide, 4-[2-[[5-bromo-2-(1H-indazol-5-ylamino)-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 511246-41-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-5-yl-N4-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 511246-40-5


CMF C18 H15 Br N6



CM 2

10/734039


CRN 76-05-1  
CMF C2 H F3 O2



RN 511246-43-8 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-5-yl-N4-[(2-methylphenyl)methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 511246-42-7  
CMF C19 H17 Br N6



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 511246-45-0 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-5-yl-N4-(1-phenylethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 511246-44-9  
CMF C19 H17 Br N6

Cc1c(NC2=CC=CC=C2)c3cc(NC4=CC=CC=C4)nc3c1Br


CRN 76-05-1  
CMF C2 H F3 O2



CRN 511246-46-1  
CMF C18 H14 Br F N6



CRN 76-05-1  
CMF C2 H F3 O2



RN	511246-50-7	CAPLUS
CN	2,4-Pyrimidinediamine, 5-bromo-N4-[(2,5-difluorophenyl)methyl]-N2-1H-indazol-5-yl-, trifluoroacetate (9CI) (CA INDEX NAME)	




10/734039

CM 1

CRN 511246-49-4


CMF C18 H13 Br F2 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 511246-60-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-5-yl-N4-[[2-(trifluoromethyl)phenyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 511246-59-6


CMF C19 H14 Br F3 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 511246-63-2 CAPLUS


10/734039

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3,4-difluorophenyl)methyl]-N2-1H-indazol-5-yl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 511246-62-1


CMF C18 H13 Br F2 N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 511246-65-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3,5-difluorophenyl)methyl]-N2-1H-indazol-5-yl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 511246-64-3

CMF C18 H13 Br F2 N6




CM 2

CRN 76-05-1

CMF C2 H F3 O2


10/734039



RN 511246-68-7 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-5-yl-N4-(2-phenylethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 511246-67-6  
CMF C19 H17 Br N6




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 511246-86-9 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-5-yl-N4-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)




RN 511246-97-2 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-5-yl-N4-(2-thienylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


10/734039

CRN 511246-96-1  
CMF C16 H13 Br N6 S



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 511246-99-4 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3,5-dichlorophenyl)methyl]-N2-1H-indazol-5-yl-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 511246-98-3  
CMF C18 H13 Br Cl2 N6



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 511247-01-1 CAPLUS  
CN 2,4-Pyrimidinediamine, N4-([1,1'-biphenyl]-3-ylmethyl)-5-bromo-N2-1H-indazol-5-yl-, trifluoroacetate (9CI) (CA INDEX NAME)

10/734039

CM 1

CRN 511247-00-0


CMF C24 H19 Br N6



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 511247-03-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-5-yl-N4-[2-(3-methoxyphenyl)ethyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 511247-02-2


CMF C20 H19 Br N6 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 511247-11-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[2-(5-fluoro-1H-indol-3-yl)ethyl]-N2-1H-


10/734039

indazol-5-yl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 511247-10-2


CMF C21 H17 Br F N7



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 511247-18-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[1-(4-bromophenyl)ethyl]-N2-1H-indazol-5-yl-, hydrochloride (9CI) (CA INDEX NAME)




●<sub>x</sub> HCl

RN 511247-19-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3-chloro-4-methylphenyl)methyl]-N2-1H-indazol-5-yl-, hydrochloride (9CI) (CA INDEX NAME)


10/734039



●x HCl

RN 511247-20-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-5-yl-N4-[(4-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 511247-21-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-5-yl-N4-[[4-(trifluoromethyl)phenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 511247-22-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(2,5-dichlorophenyl)methyl]-N2-1H-indazol-5-yl-, hydrochloride (9CI) (CA INDEX NAME)


10/734039



●x HCl


RN 511247-23-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N2-1H-indazol-5-yl-N4-[2-(trifluoromethyl)phenyl]methyl- (9CI) (CA INDEX NAME)




RN 511247-37-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(3-chlorophenyl)-5-fluoro-N2-1H-indazol-5-yl-N4-methyl- (9CI) (CA INDEX NAME)



RN 511247-54-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N2-1H-indazol-6-yl-N4-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 511247-55-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(2-furanylmethyl)-N2-1H-indazol-6-yl- (9CI) (CA INDEX NAME)




10/734039



RN 511247-56-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[1-(4-bromophenyl)ethyl]-N2-1H-indazol-6-yl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 511247-57-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3,4-dichlorophenyl)methyl]-N2-1H-indazol-6-yl- (9CI) (CA INDEX NAME)



RN 511247-58-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(1,3-benzodioxol-5-ylmethyl)-5-bromo-N2-1H-indazol-6-yl- (9CI) (CA INDEX NAME)




RN 511247-59-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(4-chlorophenyl)methyl]-N2-1H-indazol-6-yl- (9CI) (CA INDEX NAME)


Clc1ccc(cc1)CCNc2ncnc(Nc3ccc4c(c3)ncn4)c2Br

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-6-yl-N4-(1-methyl-1-phenylethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CRN 511247-62-4  
CMF C20 H19 Br N6




CRN 76-05-1  
CMF C2 H F3 O2



CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(2,5-dichlorophenyl)methyl]-N2-1H-indazol-6-yl-, trifluoroacetate (9CI) (CA INDEX NAME)

CRN 511247-64-6  
CMF C18 H13 Br Cl2 N6


10/734039



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 511247-66-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3-chloro-4-methylphenyl)methyl]-N2-1H-indazol-6-yl- (9CI) (CA INDEX NAME)



RN 511247-67-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-6-yl-N4-[(4-methoxyphenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 511247-68-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-6-yl-N4-[[4-(trifluoromethyl)phenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)


10/734039



●x HCl


RN 511247-70-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(2,4-dichlorophenyl)methyl]-N2-1H-indazol-6-yl- (9CI) (CA INDEX NAME)




RN 511247-71-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-6-yl-N4-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 511247-72-6 CAPLUS


CN Benzenesulfonamide, 4-[2-[[5-bromo-2-(1H-indazol-6-ylamino)-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 511247-74-8 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[(3,5-dichlorophenyl)methyl]-N2-1H-indazol-6-yl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

10/734039




RN 511247-86-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N4-[2-(2-pyridinyl)ethyl]-N2-6-quinolinyl-  
(9CI) (CA INDEX NAME)



RN 511247-89-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(2-methylphenyl)methyl]-N2-6-quinolinyl-  
(9CI) (CA INDEX NAME)




RN 511247-91-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(1-phenylethyl)-N2-6-quinolinyl-,  
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 511247-90-8

CMF C21 H18 Br N5




CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/734039




RN 511247-92-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[1-(4-bromophenyl)ethyl]-N2-6-quinolinyl-  
(9CI) (CA INDEX NAME)




RN 511247-93-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3,5-dichlorophenyl)methyl]-N2-6-  
quinolinyl- (9CI) (CA INDEX NAME)




RN 511247-94-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(2,4-dichlorophenyl)methyl]-N2-6-  
quinolinyl- (9CI) (CA INDEX NAME)



RN 511247-95-3 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3,4-dichlorophenyl)methyl]-N2-6-  
quinolinyl- (9CI) (CA INDEX NAME)



RN 511247-96-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(1,3-benzodioxol-5-ylmethyl)-5-bromo-N2-6-  
quinolinyl- (9CI) (CA INDEX NAME)

10/734039




RN 511247-97-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(4-chlorophenyl)methyl]-N2-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 511247-99-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(2,5-dichlorophenyl)methyl]-N2-6-quinolinyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 511248-00-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3-chloro-4-methylphenyl)methyl]-N2-6-quinolinyl- (9CI) (CA INDEX NAME)



RN 511248-02-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-6-quinolinyl-N4-[[4-(trifluoromethyl)phenyl)methyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 511248-01-4

CMF C21 H15 Br F3 N5


10/734039



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 511248-04-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(2-fluorophenyl)methyl]-N2-6-quinolinyl-  
(9CI) (CA INDEX NAME)



RN 511248-05-8 CAPLUS

CN Benzenesulfonamide, 4-[2-[[5-bromo-2-(6-quinolinylamino)-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 511248-08-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N2-(1-methyl-1H-indazol-6-yl)-N4-(1-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)




10/734039



●x HCl

RN 511248-09-2 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[(3,5-dichlorophenyl)methyl]-N2-(1-methyl-1H-indazol-6-yl)-5-(trifluoromethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 511248-10-5 CAPLUS


CN Benzenesulfonamide, 4-[2-[[5-bromo-2-[(1-methyl-1H-indazol-6-yl)amino]-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 511248-12-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-(1-methyl-1H-indazol-6-yl)-N4-(1-methyl-1-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)


10/734039



●x HCl

RN 511248-13-8 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(2,5-dichlorophenyl)methyl]-N2-(1-methyl-1H-indazol-6-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 511248-14-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3-chloro-4-methylphenyl)methyl]-N2-(1-methyl-1H-indazol-6-yl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 511248-15-0 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[1-(4-bromophenyl)ethyl]-N2-(1-methyl-1H-indazol-6-yl)- (9CI) (CA INDEX NAME)

10/734039




RN 511248-16-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-(1-methyl-1H-indazol-6-yl)-N4-(1-phenylethyl)- (9CI) (CA INDEX NAME)




RN 511248-17-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3,4-dichlorophenyl)methyl]-N2-(1-methyl-1H-indazol-6-yl)- (9CI) (CA INDEX NAME)



RN 511248-18-3 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(2-furanylmethyl)-N2-(1-methyl-1H-indazol-6-yl)- (9CI) (CA INDEX NAME)



RN 511248-19-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(3,5-dichlorophenyl)methyl]-N2-(1-methyl-1H-indazol-6-yl)- (9CI) (CA INDEX NAME)

10/734039




RN 511248-20-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(2,4-dichlorophenyl)methyl]-N2-(1-methyl-1H-indazol-6-yl)- (9CI) (CA INDEX NAME)




RN 511248-21-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(1,3-benzodioxol-5-ylmethyl)-5-bromo-N2-(1-methyl-1H-indazol-6-yl)- (9CI) (CA INDEX NAME)



RN 511248-22-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(4-chlorophenyl)methyl]-N2-(1-methyl-1H-indazol-6-yl)- (9CI) (CA INDEX NAME)



RN 511248-24-1 CAPLUS


CN Benzenesulfonamide, 4-[2-[[5-bromo-2-[(1-methyl-1H-indazol-5-yl)amino]-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)

10/734039




RN 511248-25-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-(1-methyl-1H-indazol-5-yl)-N4-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 511248-26-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[1-(4-bromophenyl)ethyl]-N2-(1-methyl-1H-indazol-5-yl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 511248-29-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-(1-methyl-1H-indazol-5-yl)-N4-(1-methyl-1-phenylethyl)-, hydrochloride (9CI) (CA INDEX NAME)


10/734039



●x HCl

RN 511248-30-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(2,5-dichlorophenyl)methyl]-N2-(1-methyl-1H-indazol-5-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 511248-31-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[(4-methoxyphenyl)methyl]-N2-(1-methyl-1H-indazol-5-yl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 511248-32-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-(1-methyl-1H-indazol-5-yl)-N4-[(4-(trifluoromethyl)phenyl)methyl]-, hydrochloride (9CI) (CA INDEX NAME)


10/734039



●x HCl

RN 511248-33-2 CAPLUS


CN 2,4-Pyrimidinediamine, 5-fluoro-N2-(1-methyl-1H-indazol-5-yl)-N4-(1-phenylethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 511248-38-7 CAPLUS

CN Benzenesulfonamide, 4-[2-[[5-bromo-2-[(1-ethyl-1H-indazol-5-yl)amino]-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 511248-39-8 CAPLUS


CN 2,4-Pyrimidinediamine, N2-6-benzothiazolyl-5-fluoro-N4-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



10/734039


RN 511248-40-1 CAPLUS

CN Benzenesulfonamide, 4-[2-[[2-(6-benzothiazolylamino)-5-fluoro-4-pyrimidinyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 511248-49-0 CAPLUS

CN 4-Pyrimidineacetonitrile, 2-(6-benzothiazolylamino)- $\alpha$ -(3-bromophenyl)- (9CI) (CA INDEX NAME)




RN 511248-52-5 CAPLUS

CN 4-Pyrimidineacetonitrile, 5-fluoro-2-(1H-indazol-6-ylamino)- $\alpha$ -(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 511248-53-6 CAPLUS

CN 4-Pyrimidineacetonitrile, 5-fluoro- $\alpha$ -(2-fluorophenyl)-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)




RN 511248-54-7 CAPLUS

CN 4-Pyrimidineacetonitrile,  $\alpha$ -1,3-benzodioxol-5-yl-5-bromo-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)




10/734039



RN 511248-55-8 CAPLUS

CN 4-Pyrimidineacetonitrile, 5-bromo- $\alpha$ -(4-cyanophenyl)-2-(1H-indazol-6-ylamino)- (9CI) (CA INDEX NAME)




RN 511248-57-0 CAPLUS

CN 4-Pyrimidineacetonitrile, 5-bromo-2-(1H-indazol-6-ylamino)- $\alpha$ -(4-nitrophenyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 511248-56-9


CMF C19 H12 Br N7 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 511248-59-2 CAPLUS


CN 4-Pyrimidineacetonitrile, 5-bromo-2-(1H-indazol-6-ylamino)- $\alpha$ -3-pyridinyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 511248-58-1

CMF C18 H12 Br N7


10/734039



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 511248-81-0 CAPLUS

CN 4-Pyrimidineacetonitrile, 5-bromo- $\alpha$ -(4-nitrophenyl)-2-(6-quinolinylamino)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 511248-80-9


CMF C21 H13 Br N6 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 32 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:927413 CAPLUS

DN 138:14070

TI CDK inhibiting pyrimidines

IN Brumby, Thomas; Jautelat, Rolf; Prien, Olaf; Schaefer, Martina;

10/734039

Siemeister, Gerhard; Luecking, Ulrich; Huwe, Christoph

PA Schering Aktiengesellschaft, Germany

SO PCT Int. Appl., 240 pp.


CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096888	A1	20021205	WO 2002-EP5669	20020523
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10127581	A1	20030102	DE 2001-10127581	20010529
	DE 10212098	A1	20031023	DE 2002-10212098	20020311
	CA 2449118	AA	20021205	CA 2002-2449118	20020523
	NZ 529654	A	20031219	NZ 2002-529654	20020523
	EP 1392662	A1	20040303	EP 2002-738100	20020523
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002009774	A	20040601	BR 2002-9774	20020523
	JP 2004535414	T2	20041125	JP 2003-500067	20020523
	US 2004102630	A1	20040527	US 2002-156759	20021107
	US 2004224966	A1	20041111	US 2004-842419	20040511
PRAI	DE 2001-10127581	A	20010529		
	DE 2002-10212098	A	20020311		
	WO 2002-EP5669	W	20020523		
	US 2002-156759	A3	20021107		
OS	MARPAT 138:14070				
IT	477588-01-5P 477588-02-6P 477588-03-7P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation and cyclin-dependent kinase inhibition of arylaminopyrimidines)				
RN	477588-01-5 CAPLUS				
CN	2,4-Pyrimidinediamine, 5-bromo-N2-1H-indazol-5-yl-N4-2-propynyl- (9CI)				
	(CA INDEX NAME)				



RN 477588-02-6 CAPLUS


CN 2,4-Pyrimidinediamine, N2-5-benzothiazolyl-5-bromo-N4-2-propynyl- (9CI)  
(CA INDEX NAME)

10/734039



RN 477588-03-7 CAPLUS

CN 1H-Indol-5-amine, N-[5-bromo-4-(2-propynylamino)-2-pyrimidinyl]-2,3-dihydro-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)



IT 477588-99-1P 477589-05-2P 477589-06-3P

477589-15-4P 477590-09-3P 477590-10-6P

477590-11-7P 477590-12-8P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and cyclin-dependent kinase inhibition of arylaminopyrimidines)

RN 477588-99-1 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 5-[[5-bromo-4-[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477589-05-2 CAPLUS

CN 1-Butanol, 2-[[2-(1,3-benzodioxol-5-ylamino)-5-bromo-4-pyrimidinyl]amino]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477589-06-3 CAPLUS

10/734039

CN 1-Butanol, 2-[[2-(1H-benzotriazol-5-ylamino)-5-bromo-4-pyrimidinyl]amino]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477589-15-4 CAPLUS

CN 1-Butanol, 2-[[5-bromo-2-(1H-indol-5-ylamino)-4-pyrimidinyl]amino]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477590-09-3 CAPLUS

CN 1-Naphthalenesulfonamide, 5-[[5-bromo-4-[[[(1S)-2-hydroxy-1-methylethyl]amino]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477590-10-6 CAPLUS

CN 1H-Indole-1-sulfonamide, 5-[[5-bromo-4-[[[(1S)-2-hydroxy-1-methylethyl]amino]-2-pyrimidinyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/734039



RN 477590-11-7 CAPLUS

CN 1H-Indole-1-sulfonamide, 4-[[5-bromo-4-[(1S)-2-hydroxy-1-methylethyl]amino]-2-pyrimidinyl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477590-12-8 CAPLUS

CN 1-Propanol, 2-[[5-bromo-2-[(3,4-dihydro-1,1-dioxido-2H-1,2-benzothiazin-7-yl)amino]-4-pyrimidinyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 33 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:805369 CAPLUS

DN 138:238114

TI Synthesis of 4-(trihalomethyl)dipyrimidin-2-ylamines from  
beta-alkoxy-alpha,beta-unsaturated trihalomethyl ketones

AU Zanatta, Nilo; Lopes, Elizandra C. S.; Fantinel, Leonardo; Bonacorso,  
Helio G.; Martins, Marcos A. P.

CS Nucleo de Quimica de Heterociclos (NUQUIMHE), DEp. de Quimica, Univ.  
Federal de Santa Maria, Santa Maria, Brazil


SO Journal of Heterocyclic Chemistry (2002), 39(5), 943-947  
CODEN: JHTCAD; ISSN: 0022-152X

PB HeteroCorporation

10/734039

DT Journal  
LA English  
OS CASREACT 138:238114  
IT 502162-67-6P 502162-68-7P 502162-71-2P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of [(trihalomethyl)pyrimidinyl]amines from  $\beta$ -alkoxy-  
 $\alpha,\beta$ -unsatd. trihalomethyl ketones and  
[(trichloromethyl)pyrimidinyl]guanidine)  
RN 502162-67-6 CAPLUS  
CN Furo[2,3-d]pyrimidin-4-ol, 1,4,4a,5,6,7a-hexahydro-2-[[4-(trichloromethyl)-  
2-pyrimidinyl]amino]-4-(trifluoromethyl)-, (4aR,7aS)-rel- (9CI) (CA INDEX  
NAME)


Relative stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 502162-68-7 CAPLUS  
CN 4H-Pyrano[2,3-d]pyrimidin-4-ol, 1,4a,5,6,7,8a-hexahydro-2-[[4-(  
trichloromethyl)-2-pyrimidinyl]amino]-4-(trifluoromethyl)-,  
(4aR,8aR)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 502162-71-2 CAPLUS  
CN 4H-Pyrano[2,3-d]pyrimidin-4-one, 1,4a,5,6,7,8a-hexahydro-2-[[4-(  
trichloromethyl)-2-pyrimidinyl]amino]-, (4aR,8aS)-rel- (9CI) (CA INDEX  
NAME)

Relative stereochemistry.




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD

## ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 34 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2001:833291 CAPLUS  
 DN 135:357949  
 TI Synthesis of substituted amino pyrimidine/triazine derivatives as 5-HT7  
 receptor antagonists  
 IN Poss, Michael A.; Purandare, Ashok V.; Mattson, Ronald J.; Sun, Li-qiang  
 PA Bristol-Myers Squibb Company, USA  
 SO PCT Int. Appl., 99 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085701	A1	20011115	WO 2001-US13324	20010425
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002032199	A1	20020314	US 2001-841273	20010424
	US 6630469	B2	20031007		
	CA 2409729	AA	20011115	CA 2001-2409729	20010425
	EP 1280781	A1	20030205	EP 2001-928857	20010425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003532714	T2	20031105	JP 2001-582302	20010425
PRAI	US 2000-202931P	P	20000509		
	WO 2001-US13324	W	20010425		
OS	MARPAT 135:357949				
IT	372182-50-8P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (drug; synthesis of substituted amino pyrimidine/triazine derivs. as 5-HT7 receptor antagonists)				
RN	372182-50-8 CAPLUS				
CN	2,4-Pyrimidinediamine, N2-(2,3-dihydro-1H-inden-2-yl)-N4-(1-phenylethyl)- (9CI) (CA INDEX NAME)				



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 35 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2001:816647 CAPLUS  
 DN 135:357948  
 TI Preparation of heterocyclic compounds as phosphodiesterase V (PDE V)  
 inhibitors



10/734039

IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei  
 PA Tanabe Seiyaku Co., Ltd., Japan  
 SO PCT Int. Appl., 207 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001041142	A5	20011112	AU 2001-41142	20010315
	CA 2407231	AA	20021023	CA 2001-2407231	20010315
	EP 1277741	A1	20030122	EP 2001-912373	20010315
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 522217	A	20040430	NZ 2001-522217	20010315
	US 2003229089	A1	20031211	US 2002-258545	20021025
	US 2004142930	A1	20040722	US 2003-699804	20031104
PRAI	JP 2000-130371	A	20000428		
	JP 2000-277652	A	20000913		
	WO 2001-JP2034	W	20010315		
	US 2002-258545	A2	20021025		
OS	MARPAT 135:357948				
IT	372114-55-1P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of heterocyclic compds. as phosphodiesterase V inhibitors preventive or therapeutic agents for various diseases due to dysfunction of signal transduction through cGMP)				
RN	372114-55-1 CAPLUS				
CN	5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2,3-dihydro-1H-inden-2-yl)amino]-N-(2-pyridinylmethyl)-(9CI) (CA INDEX NAME)				




RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD

## ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 36 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2000:725470 CAPLUS  
 DN 133:296440  
 TI Preparation of phthalazines for treating inflammatory diseases  
 IN Bold, Guido; Dawson, King Janet; Frei, Jorg; Heng, Richard; Manley, Paul  
 William; Wietfeld, Bernhard; Wood, Jeanette Marjorie  
 PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft  
 m.b.H.; Dawson King, Janet  
 SO PCT Int. Appl., 127 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059509	A1	20001012	WO 2000-EP2726	20000328
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2366857	AA	20001012	CA 2000-2366857	20000328
	EP 1165085	A1	20020102	EP 2000-920604	20000328
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 2000009507	A	20020115	BR 2000-9507	20000328
	JP 2002541108	T2	20021203	JP 2000-609072	20000328
	AU 766081	B2	20031009	AU 2000-41125	20000328
	NO 2001004655	A	20011019	NO 2001-4655	20010925
	US 2003013718	A1	20030116	US 2001-964025	20010926
	US 6686347	B2	20040203		
	US 2004142934	A1	20040722	US 2003-723238	20031126
	US 6911440	B2	20050628		
	US 2005176711	A1	20050811	US 2005-99292	20050405
PRAI	CH 1999-603	A	19990330		
	GB 1999-16064	A	19990708		
	WO 2000-EP2726	W	20000328		
	US 2001-964025	A3	20010926		
	US 2003-723238	A3	20031126		
OS	MARPAT 133:296440				
IT	300842-79-9P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of phthalazines for treating inflammatory diseases)				
RN	300842-79-9 CAPLUS				
CN	1-Phthalazinamine, N-(4-methyl-2-pyrimidinyl)-4-(4-pyridinylmethyl)- (9CI)				
	(CA INDEX NAME)				


10/734039



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 37 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2000:227963 CAPLUS  
DN 132:255752  
TI Use of ninhydrin derivatives for coloring keratin-containing fibers  
IN Moeller, Hinrich; Hoeffkes, Horst; Oberkobusch, Doris  
PA Henkel K.-G.a.A., Germany  
SO Ger. Offen., 14 pp.  
CODEN: GWXXBX  
DT Patent  
LA German  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19845481	A1	20000406	DE 1998-19845481	19981002
PRAI	DE 1998-19845481		19981002		
OS	MARPAT 132:255752				
IT	262613-74-1				
RL:	BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (ninhydrin derivs. for coloring keratin-containing fibers)				
RN	262613-74-1	CAPLUS			
CN	1H-Indene-1,3(2H)-dione, 2-hydroxy-2-[(4-methyl-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)				



L4 ANSWER 38 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2000:191092 CAPLUS  
DN 132:222659

10/734039

TI Preparation of aminoalkylphosphonic ester derivatives as cell adhesion inhibitors  
IN Kono, Yasushi; Sawada, Takayuki; Nomura, Masahiro; Takahashi, Yukie; Tsubuki, Takeshi; Sakoe, Yasuhiko; Kuriyama, Kazuhiko  
PA Kyorin Pharmaceutical Co., Ltd., Japan  
SO PCT Int. Appl., 55 pp.  
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000015645	A1	20000323	WO 1999-JP4913	19990910
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9956485	A1	20000403	AU 1999-56485	19990910
PRAI	JP 1998-258841	A	19980911		
	WO 1999-JP4913	W	19990910		


OS MARPAT 132:222659

IT 261617-03-2P 261617-04-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of aminoalkylphosphonic ester derivs. as cell adhesion inhibitors and drugs)


RN 261617-03-2 CAPLUS

CN Phosphonic acid, [[[[[5-[[4-(trifluoromethyl)-2-pyrimidinyl]amino]-1-naphthalenyl]oxy]acetyl]amino]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 261617-04-3 CAPLUS

CN Phosphonic acid, [2-[[[[[5-[[4-(trifluoromethyl)-2-pyrimidinyl]amino]-1-naphthalenyl]oxy]acetyl]amino]ethyl]-, diethyl ester (9CI) (CA INDEX NAME)




RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 39 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1999:505664 CAPLUS  
DN 131:144609  
TI Preparation of pyrimidinecarboxylates and analogs as transcription factor  
activation inhibitors  
IN Suto, Mark J.; Gayo, Leah M.; Palanki, Moorthy S. S.; Ransone-Fong, Lynn  
J.  
PA Signal Pharmaceuticals, Inc., USA  
SO U.S., 32 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5935966	A	19990810	US 1997-807677	19970227
	US 5852028	A	19981222	US 1995-574406	19951218
	WO 9709325	A1	19970313	WO 1996-US14089	19960830
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
	WO 9838171	A1	19980903	WO 1998-US3616	19980224
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9866667	A1	19980918	AU 1998-66667	19980224
PRAI	US 1995-3109P	P	19950901		
	US 1995-574406	A2	19951218		
	WO 1996-US14089	W	19960830		
	US 1997-807677	A	19970227		
	WO 1998-US3616	W	19980224		
OS	MARPAT 131:144609				
IT	188936-13-2P 188936-55-2P 188936-56-3P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyrimidinecarboxylates and analogs as transcription factor activation inhibitors)				
RN	188936-13-2 CAPLUS				


10/734039

CN 5-Pyrimidinecarboxylic acid, 2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)amino]-4-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 188936-55-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[(1,3-dihydro-5-methyl-1,3-dioxo-2H-isoindol-2-yl)amino]-4-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 188936-56-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[(5,6-dichloro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)amino]-4-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 40 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1998:608604 CAPLUS

DN 129:216625

TI Preparation of pyrimidinecarboxylates for treating inflammatory conditions  
IN Suto, Mark J.; Gayo, Leah M.; Palanki, Moorthy S. S.; Ransone-Fong, Lynn J.

PA Signal Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

-----

----


-----

-----


-----

10/734039


PI WO 9838171 A1 19980903 WO 1998-US3616 19980224  
W: AU, CA, JP  
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE  
US 5935966 A 19990810 US 1997-807677 19970227  
AU 9866667 A1 19980918 AU 1998-66667 19980224  
PRAI US 1997-807677 A 19970227  
US 1995-3109P P 19950901  
US 1995-574406 A2 19951218  
WO 1996-US14089 W 19960830  
WO 1998-US3616 W 19980224  
OS MARPAT 129:216625  
IT 188936-13-2P 188936-55-2P 188936-56-3P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyrimidinecarboxylates for treating inflammatory conditions)  
RN 188936-13-2 CAPLUS  
CN 5-Pyrimidinecarboxylic acid, 2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)amino]-4-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 188936-55-2 CAPLUS  
CN 5-Pyrimidinecarboxylic acid, 2-[(1,3-dihydro-5-methyl-1,3-dioxo-2H-isoindol-2-yl)amino]-4-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 188936-56-3 CAPLUS  
CN 5-Pyrimidinecarboxylic acid, 2-[(5,6-dichloro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)amino]-4-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)




10/734039

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 41 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1997:302930 CAPLUS  
DN 126:277492  
TI Preparation of pyrimidinecarboxylates and related compounds for treating  
inflammatory conditions  
IN Suto, Mark J.; Gayo, Leah M.; Palanki, Moorthy S. S.; Ransone-Fong, Lynn  
J.  
PA Signal Pharmaceuticals, Inc., USA; Suto, Mark J.; Gayo, Leah M.; Palanki,  
Moorthy, S. S.; Ransone-Fong, Lynn J.  
SO PCT Int. Appl., 81 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 4


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9709325	A1	19970313	WO 1996-US14089	19960830
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
	US 5852028	A	19981222	US 1995-574406	19951218
	CA 2230896	AA	19970313	CA 1996-2230896	19960830
	AU 9670130	A1	19970327	AU 1996-70130	19960830
	AU 726058	B2	20001026		
	JP 11512390	T2	19991026	JP 1996-511324	19960830
	US 5935966	A	19990810	US 1997-807677	19970227
PRAI	US 1995-3109P	P	19950901		
	US 1995-574406	A	19951218		
	WO 1996-US14089	W	19960830		
OS	MARPAT 126:277492				
IT	188936-13-2P 188936-55-2P 188936-56-3P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyrimidinecarboxylates and related compds. for treating inflammatory conditions)				
RN	188936-13-2 CAPLUS				
CN	5-Pyrimidinecarboxylic acid, 2-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)amino]-4-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)				



RN 188936-55-2 CAPLUS  
CN 5-Pyrimidinecarboxylic acid, 2-[(1,3-dihydro-5-methyl-1,3-dioxo-2H-isoindol-2-yl)amino]-4-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)




10/734039



RN 188936-56-3 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[(5,6-dichloro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)amino]-4-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 42 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1987:102333 CAPLUS

DN 106:102333

TI Preparation of herbicidal benzolactam sultams

IN Diehr, Hans Joachim; Fest, Christa; Kirsten, Rolf; Kluth, Joachim; Mueller, Klaus Helmut; Pfister, Theodor; Priesnitz, Uwe; Riebel, Hans Jochem; Roy, Wolfgang; et al.

PA Bayer A.-G., Fed. Rep. Ger.

SO Ger. Offen., 54 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3517845	A1	19861120	DE 1985-3517845	19850517
	EP 203220	A1	19861203	EP 1985-110829	19850819
	R: CH, DE, FR, GB, IT, LI				
	US 4645528	A	19870224	US 1985-769280	19850823
	JP 61263976	A2	19861121	JP 1985-188719	19850829
PRAI	DE 1985-3517845	A	19850517		


OS CASREACT 106:102333

IT 103864-87-5P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as herbicide)

RN 103864-87-5 CAPLUS

CN 1,2,4-Benzothiadiazepin-5(4H)-one, 4-methoxy-3-[(4-methyl-2-pyrimidinyl)amino]-, 1,1-dioxide (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 43 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1986:515087 CAPLUS  
 DN 105:115087  
 TI Heterocyclic 1-(2-hydroxyaminocarbonylphenylsulfonyl)urea derivatives  
 IN Diehr, Hans Joachim; Fest, Christa; Kirsten, Rolf; Kluth, Joachim;  
 Mueller, Klaus Helmut; Pfister, Theodor; Priesnitz, Uew; Riebel, Hans  
 Joachim; Roy, Wolfgang  
 PA Bayer A.-G. , Fed. Rep. Ger.  
 SO Ger. Offen., 62 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3516435	A1	19860313	DE 1985-3516435	19850508
	EP 173958	A2	19860312	EP 1985-110835	19850819
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	US 4704158	A	19871103	US 1985-769225	19850823
	AU 8546656	A1	19860306	AU 1985-46656	19850826
	DD 238524	A5	19860827	DD 1985-280079	19850828
	CA 1223592	A1	19870630	CA 1985-489588	19850828
	DK 8503927	A	19860301	DK 1985-3927	19850829
	JP 61069761	A2	19860410	JP 1985-188713	19850829
	ZA 8506594	A	19860430	ZA 1985-6594	19850829
	BR 8504158	A	19860624	BR 1985-4158	19850829
	HU 39075	A2	19860828	HU 1985-3283	19850829
	ES 546560	A1	19860301	ES 1985-546560	19850830
PRAI	DE 1984-3431927	A1	19840830		
	DE 1985-3516435	A	19850508		

OS CASREACT 105:115087


IT 103864-87-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation and ring cleavage of)

RN 103864-87-5 CAPLUS

CN 1,2,4-Benzothiadiazepin-5(4H)-one, 4-methoxy-3-[(4-methyl-2-pyrimidinyl)amino]-, 1,1-dioxide (9CI) (CA INDEX NAME)


10/734039



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 44 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1986:497490 CAPLUS  
DN 105:97490  
TI 1-(Phenylsulfonyl)-3-heteroarylureas  
IN Diehr, Hans Joachim; Fest, Christa; Kirsten, Rolf; Kluth, Joachim;  
Mueller, Klaus Helmut; Pfister, Theodor; Priesnitz, Uwe; Riebel, Hans  
Jojchem; Roy, Wolfgang; et al.  
PA Bayer A.-G. , Fed. Rep. Ger.  
SO Eur. Pat. Appl., 65 pp.  
CODEN: EPXXDW  
DT Patent  
LA German  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 173958	A2	19860312	EP 1985-110835	19850819
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	DE 3516435	A1	19860313	DE 1985-3516435	19850508
PRAI	DE 1984-3431927	A	19840830		
	DE 1985-3516435	A	19850508		
IT	103864-87-5P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT				
	(Reactant or reagent)				
	(preparation and ring cleavage of)				
RN	103864-87-5 CAPLUS				
CN	1,2,4-Benzothiadiazepin-5(4H)-one, 4-methoxy-3-[(4-methyl-2-pyrimidinyl)amino]-, 1,1-dioxide (9CI) (CA INDEX NAME)				




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


L4 ANSWER 45 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1981:417342 CAPLUS  
DN 95:17342  
TI Mixed ligand cobalt(III) complexes obtained by substitution in  
dinitrobis(acetylacetonato)cobaltate(III) by sulfur and nitrogen donors

10/734039

AU Mishra, L. K.; Bhushan, Himanshu  
CS Dep. Chem., Patna Univ., Patna, 800 005, India  
SO Indian Journal of Chemistry, Section A: Inorganic, Physical, Theoretical  
& Analytical (1981), 20A(4), 415-17  
CODEN: IJCADU; ISSN: 0376-4710  
DT Journal  
LA English  
IT 78036-06-3P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 78036-06-3 CAPLUS  
CN Cobalt, (4-methyl-2-pyrimidinamine-N2) (nitrito-N)bis(2,4-pentanedionato-  
O,O')-, (OC-6-11)- (9CI) (CA INDEX NAME)




L4 ANSWER 46 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1978:170124 CAPLUS  
DN 88:170124  
TI Psychoactive agents. Part VI. Synthesis and central nervous system  
effects of some 2-substituted 5-acetyl-4-methylpyrimidine derivatives  
AU Arya, V. P.; David, J.; Grewal, R. S.; Marathe, S. B.; Patil, S. D.  
CS Res. Cent., Ciba-Geigy, Bombay, India  
SO Indian Journal of Chemistry, Section B: Organic Chemistry Including  
Medicinal Chemistry (1977), 15B(12), 1129-32  
CODEN: IJSBDB; ISSN: 0376-4699  
DT Journal  
LA English  
OS CASREACT 88:170124  
IT 66373-30-6P 66373-31-7P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 66373-30-6 CAPLUS  
CN Ethanone, 1-[2-(1H-benzimidazol-2-ylamino)-4-methyl-5-pyrimidinyl]- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/734039

RN 66373-31-7 CAPLUS  
CN Ethanone, 1-[4-methyl-2-[(4-methyl-2-quinazolinyl)amino]-5-pyrimidinyl]-  
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 47 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1964:31547 CAPLUS

DN 60:31547

OREF 60:5678c-f

TI Anthraquinone dyes

IN Baumann, Fritz

PA Farbenfabriken Bayer A.-G.

SO 5 pp.

DT Patent


LA Unavailable

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1151335		19630711	DE	19570312

IT 101920-59-6, 1H-Naphth[2,3-f]isoindole-5,10-dione,  
4,11-diamino-2,3-dihydro-1,3-bis[(4-methyl-2-pyrimidinyl)imino]-  
(preparation of)

RN 101920-59-6 CAPLUS

CN 1H-Naphth[2,3-f]isoindole-5,10-dione, 4,11-diamino-2,3-dihydro-1,3-bis-[(4-methyl-2-pyrimidinyl)imino]- (6CI, 7CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 48 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1961:30413 CAPLUS

DN 55:30413

OREF 55:5968b-i,5969a-f

TI 1,4 - Diamino - 2,3 - anthraquinonedicarboximide dyes

IN Baumann, Fritz

PA Farbenfabriken Bayer Akt.-Ges.


DT Patent

LA Unavailable

FAN.CNT 1


10/734039

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2945861 GB 879240		19600719	US GB	
IT	101920-59-6, 1H-Naphth[2,3-f]isoindole-5,10-dione, 4,11-diamino-2,3-dihydro-1,3-bis(4-methyl-2-pyrimidinylimino) - (preparation of)				
RN	101920-59-6 CAPLUS				
CN	1H-Naphth[2,3-f]isoindole-5,10-dione, 4,11-diamino-2,3-dihydro-1,3-bis-[(4-methyl-2-pyrimidinyl)imino] - (6CI, 7CI) (CA INDEX NAME)				



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 49 OF 49 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1953:22276 CAPLUS  
DN 47:22276  
OREF 47:3854h-i,3855a-e  
TI Chemotherapy of malaria. V. Synthesis of 4-(thiazolyl-amino)quinolines and 4-phenoxyquinolines  
AU Ganapathi, K.; Shah, M. H.  
CS Haffkine Inst., Bombay  
SO Proceedings - Indian Academy of Sciences, Section A (1951), 34A, 178-82  
CODEN: PISAA7; ISSN: 0370-0089  
DT Journal  
LA Unavailable  
OS CASREACT 47:22276  
IT 652984-62-8, Quinoline, 7-chloro-4-(4-methyl-2-pyrimidinylamino) -  
(preparation of)  
RN 652984-62-8 CAPLUS  
CN Quinoline, 7-chloro-4-(4-methyl-2-pyrimidinylamino) - (5CI) (CA INDEX NAME)



10/734039

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

165.49

327.46

STN INTERNATIONAL LOGOFF AT 15:44:45 ON 03 DEC 2005